SCODiA Report by MLBI Lab

Single-Cell Transcriptomics Reveals Colorectal Cancer Microenvironment Remodeling and Immunosuppression

This report details single-cell RNA-seq findings from human colon tissue, highlighting profound cellular and molecular changes in colorectal cancer. Key observations include the malignant transformation of Intestinal Epithelial cells, characterized by aneuploidy and dysregulated cell cycle, along with significant shifts in immune cell populations and extensive stromal reprogramming. The tumor microenvironment is marked by increased immunosuppressive T cell and macrophage subsets, altered cell-cell communication, and a strong pro-tumorigenic fibroblast phenotype. These insights uncover potential biomarkers and therapeutic targets for colorectal cancer.

Contents

0. Dataset overview
1. UMAP Visualization of Cell Populations by Condition, Sample, Cell Type, and Ploidy in Colon Tissue
2. Major Cell Type Score and Ploidy Distribution on UMAP
3. Celltype Subset Marker Expression Validation
4. Intestinal Epithelial Cells (Tumor Origin) CNV Heatmap and Amplification Summary
5. CNV-based UMAP Analysis of Colon Tissue Cells
6. Minor Cell Type Population Analysis in Colon Normal vs. Tumor Tissue
7. T cell Subsets Population Analysis in Normal and Colon Tumor Tissues
8. T cell Subset Population Shifts in Colon Cancer
9. Macrophage Subpopulation Shifts in Colon Cancer
10. Macrophage Subset Population Shifts in Colon Tumor Microenvironment
11. Intestinal Epithelial Cell Ploidy Distribution in Normal vs. Tumor Conditions
12. Colon Cell-Cell Interaction Patterns in Normal and Tumor Conditions
13. Immune Checkpoint and Cell Cycle Gene-Associated Cell-Cell Interactions in Colon Normal vs. Tumor Microenvironments
14. Condition-Specific Cell-Cell Interaction Patterns in Normal and Tumor Colon Tissue
15. Intestinal Epithelial Cell의 조건 특이적 표면 마커 발현 패턴 분석
16. Surfaceome Marker Characterization of Colon Cell Subtypes
17. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue
18. T cell CD4+ Condition-Specific Surfaceome Markers in Colon Tissue
19. Dysregulation of Cell Cycle Pathway Genes in Intestinal Epithelial Cells of Colon Tumors
20. Gene Ontology (GSA) Analysis of Intestinal Epithelial Cells in Colon Tissue
21. Gene Set Enrichment Analysis (GSEA) of Intestinal Epithelial Cells, CD4+ T Cells, and Fibroblasts in Colon Tissue
22. Discussion
23. Query List

0. Dataset overview

Dataset Summary

• 이 데이터는 48033개의 세포와 20683개의 유전자로 구성된 단일 세포 RNA 시퀀싱 데이터셋입니다.
• 인간 대장 조직에서 유래했으며, 'normal'과 'tumor' 두 가지 조건이 포함되어 있습니다.
• 세포 주석은 'celltype_major', 'celltype_minor', 'celltype_subset'의 세 가지 수준으로 제공됩니다.
• celltype_major: T cell, B cell, Intestinal Epithelial cell, Stromal cell, Myeloid cell, Endothelial cell, Mast cell 등
• celltype_minor: T cell CD4+, Plasma cell, Fibroblast, Macrophage, Dendritic cell, NK cell 등
• celltype_subset: T cell (Naive), Goblet cell, Enterocyte, Macrophage (M2A) 등 세분화된 세포 타입
• 각 세포는 'Diploid' 또는 'Aneuploid'로 분류된 'ploidy_dec' 정보도 가지고 있습니다.

Precomputed Results

• Cell-Cell Interaction (CCI): 'uns['CCI']' 및 'uns['CCI_sample']'에 저장되어 있으며, 조건 및 샘플별 세포 간 상호작용 분석 결과입니다.
• Differential Expression Genes (DEG): 'uns['DEG']'에 저장되어 있으며, 각 'celltype_minor'에 대해 조건 간의 유전자 발현 차이 분석 결과입니다.
• Gene Set Enrichment Analysis (GSEA): 'uns['GSEA']'에 저장되어 있으며, 각 'celltype_minor'에 대한 GSEA 분석 결과입니다.
• Gene Ontology (GO) / Gene Set Analysis (GSA): 'uns['GSA_up']'에 저장되어 있으며, 각 'celltype_minor'에 대한 GO/GSA 분석 결과입니다.

1. UMAP Visualization of Cell Populations by Condition, Sample, Cell Type, and Ploidy in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP visualizations of single-cell RNA-seq data from human colon tissue, dissecting cellular heterogeneity across various biological and technical annotations. The UMAP plots allow for an assessment of the overall structure of the dataset, the quality of cell type annotations, the presence of batch effects, and the distribution of cells from normal and tumor conditions, including those with aneuploid status.

Visual Summary

The UMAPs display the relationships between 48,033 cells based on their transcriptional profiles, colored by six different metadata categories: condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset.

• Condition: The UMAP shows cells from 'normal' and 'tumor' conditions. While there are regions where normal and tumor cells are intermingled, suggesting shared cell types or states across conditions, certain clusters, particularly a large cluster on the top right and a smaller one on the bottom left, are highly enriched for 'tumor' cells. Other areas appear predominantly 'normal'. This indicates both commonalities and distinct populations between disease states.
• Sample: The distribution of cells colored by individual sample IDs (e.g., T_cac1, B_cac4) shows a generally good mixing of cells from different samples across most major clusters. This suggests that the primary UMAP structure is driven by biological variation rather than strong sample-specific batch effects, which is crucial for robust comparisons. However, some smaller clusters exhibit higher enrichment for specific samples, which may reflect individual biological heterogeneity or minor sample-specific characteristics.
• Major Cell Type (celltype_major): The major cell types show clear segregation into distinct, well-defined clusters. For instance, 'T cell' forms prominent clusters (light blue) in the central and lower-left regions, 'Intestinal Epithelial cell' (light orange) forms a large, distinct cluster in the top-right, and 'B cell' (maroon) and 'Stromal cell' (light green) occupy other well-separated areas. The minimal presence of 'unassigned' cells (dark purple) scattered sparsely across the UMAP indicates effective broad cell type annotation.
• Minor Cell Type (celltype_minor): This panel provides a more granular view within the major cell types. For example, within the T cell compartment, 'T cell CD4+' (dark blue) and 'T cell CD8+' (medium blue) show distinct separation. 'Plasma cell' (light green) is clearly distinguishable from the main 'B cell' cluster. Similarly, sub-types of Myeloid cells like 'Macrophage' (yellow) and 'Dendritic cell' (red) are discernible, indicating good resolution at this level.
• Ploidy Status (ploidy_dec): The UMAP highlights the distribution of cells inferred as 'Aneuploid' (maroon) or 'Diploid' (yellow). Aneuploid cells largely co-localize with the prominent 'Intestinal Epithelial cell' cluster (top right), which was previously observed to be highly enriched in 'tumor' cells. The majority of the remaining cells across the UMAP are 'Diploid'. 'Unclear' cells (dark purple) are very few. This is a strong signal suggesting the identity of tumor cells.
• Cell Type Subsets (celltype_subset): This highest resolution annotation shows remarkable heterogeneity within the minor cell types. Within the T cell compartment, various helper T cell subsets (e.g., Th1, Th17, Treg) and cytotoxic T cells are clearly delineated. Epithelial cells exhibit diversity, including 'Goblet cell', 'Paneth cell', 'Enterocyte', and 'Crypt cell'. B cell subsets (e.g., 'B cell (Memory)', 'Breg') and myeloid subsets (e.g., 'Macrophage (M1)', 'DC (Plasmacytoid)') are also well-resolved into distinct clusters.

Biological Interpretation

1. Robust Cell Type Identification: The clear and hierarchical segregation of cell populations from major to subset levels confirms a high-quality annotation strategy and robust clustering. The distinct clustering of celltype_major, celltype_minor, and celltype_subset demonstrates that the underlying gene expression patterns effectively distinguish diverse cell identities present in the colon tissue. The relatively low number of 'unassigned' cells further supports the comprehensiveness of the cell type annotations.
2. Tumor-Specific Cell Compartments: The condition UMAP reveals populations predominantly associated with the 'tumor' state. The most striking observation is the large Intestinal Epithelial cell cluster (top right) being highly enriched for tumor cells. This is consistent with the Intestinal Epithelial cell being the designated 'Tumor origin celltype', implying these are the transformed malignant cells.
3. Aneuploidy as a Hallmark of Cancer Cells: The ploidy_dec UMAP provides strong evidence for the identity of tumor cells. The 'Aneuploid' cells almost exclusively reside within the Intestinal Epithelial cell cluster, which itself is highly enriched in cells from 'tumor' conditions. Aneuploidy, or an abnormal number of chromosomes, is a well-established hallmark of cancer cells, confirming that these epithelial cells are indeed the malignant population within the tumor microenvironment [GeneCards - Aneuploidy: GeneCards].
4. Heterogeneity within Tumor Epithelium and Microenvironment: Even within the putatively malignant Intestinal Epithelial cell cluster, the celltype_subset map indicates diverse epithelial subtypes (e.g., Goblet, Paneth, Enterocyte, Crypt cells). This suggests either the presence of distinct malignant epithelial subclones with varying differentiation states or the persistence of non-transformed epithelial cells within the tumor context. Furthermore, the diverse immune and stromal populations observed (T cells, B cells, Myeloid cells, Fibroblasts, Endothelial cells, etc.) indicate a complex and active tumor microenvironment, where different immune and stromal cell subsets are likely interacting with the tumor cells and influencing disease progression.

Annotation Notes

The comprehensive and well-segregated UMAPs for all levels of cell type annotation, coupled with the clear distinction of normal/tumor conditions and the biological validation of aneuploidy in tumor epithelial cells, indicate a high quality of the single-cell dataset and its annotations. The effective integration, as evidenced by sample mixing, ensures that downstream differential expression and cell-cell interaction analyses will likely reflect true biological variations rather than technical artifacts.

2. Major Cell Type Score and Ploidy Distribution on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) visualizations, illustrating the distribution of various major cell type scores, inferred cellular ploidy status, and the final assigned major cell types across a single-cell RNA-seq dataset from human colon tissue. These plots collectively provide a comprehensive overview of the cellular landscape, the confidence of cell type annotations, and the genomic stability (ploidy) of different cell populations.

Visual Summary

The UMAP projections reveal a well-structured embedding with distinct clusters representing various cell populations.

• Major Cell Type Scores: Each plot for HiCAT_major_score (T cell, B cell, Myeloid cell, Mast cell, Endothelial cell, Stromal cell, Intestinal Epithelial cell) shows a strong, localized signal (yellow-green areas) in specific regions of the UMAP. These high-score regions clearly delineate distinct clusters, indicating a robust and confident assignment for most major cell types. For example, T cells and B cells form well-separated immune clusters, while Stromal and Intestinal Epithelial cells occupy different, large domains. The Enteric neuron score shows generally low values across the UMAP, with only a very small, weakly scoring region, consistent with it being a rare population or not a primary major type in the final annotation.
• Ploidy Status (ploidy_dec): The ploidy_dec plot highlights a clear separation between Aneuploid (red) and Diploid (light yellow) cells. A significant population of Aneuploid cells is clustered predominantly in one region of the UMAP, while the vast majority of other cells are classified as Diploid.
• Final Major Cell Type Assignment (celltype_major): This plot consolidates the information, showing distinct, colored clusters corresponding to the identified major cell types: B cell, Endothelial (Endo), Intestinal Epithelial (Ent.Epi), Mast cell, Myeloid, Stromal cell, T cell, and unassigned. The visual correspondence between the high-score regions in the individual cell type score plots and the final celltype_major clusters is striking, confirming the accuracy of the annotation.

Biological Interpretation

The UMAP visualizations provide critical biological insights into the cellular composition and disease state of the colon tissue:

• Robust Cell Type Annotation: The strong congruence between the HiCAT_major_score plots and the final celltype_major assignments demonstrates a high confidence in the cell type annotations. Most major cell types (e.g., T cells, B cells, Myeloid cells, Stromal cells) form cohesive, well-separated clusters, suggesting distinct transcriptional profiles. This clear separation is crucial for downstream cell-type-specific analyses.
• Identification of Malignant Cells: The co-localization of Aneuploid cells (ploidy_dec plot, red cluster) with a specific region annotated as Intestinal Epithelial cell (celltype_major plot, peach cluster) is a highly significant finding. Given that "Intestinal Epithelial cell" is specified as the "Tumor origin celltype" and aneuploidy is a hallmark of cancer, this strongly suggests that this aneuploid Intestinal Epithelial cell cluster represents the malignant tumor cells within the dataset. The remaining Diploid cells likely represent normal host cells, including various immune and stromal populations, as well as normal epithelial cells from non-tumor regions.
• Colon Tissue Cellular Heterogeneity: The presence of a diverse array of major cell types (T cell, B cell, Myeloid cell, Stromal cell, Intestinal Epithelial cell, Endothelial cell, Mast cell) is expected in colon tissue, reflecting the complex microenvironment that includes both immune surveillance and structural components, especially in the context of both normal and tumor conditions.
• Rare Cell Populations: The low scores for Enteric neuron suggest that while such cells might exist in the colon, they are either extremely rare in this dataset, not distinct enough to form a major cluster, or their representation falls under the 'unassigned' category in the final celltype_major annotation.

Annotation Notes

The consistency observed between the major cell type scores and the final assigned celltype_major clusters indicates a high quality of cell identity annotation in this dataset. The distinct clustering and clear separation of cell types enhance confidence in further cell-type-specific analyses. The ploidy_dec overlay serves as an excellent internal validation and provides critical context for identifying the malignant epithelial cell population, which is essential for understanding tumor biology in this dataset. Further investigation into the 'unassigned' cluster and potentially low-scoring populations like Enteric neuron might reveal novel or very rare cell types, but for major cell populations, the current annotations appear robust.

3. Celltype Subset Marker Expression Validation

[Analysis Visualization Results]...

Analysis Overview

This dot plot visualizes the expression of selected marker genes across different celltype_subset populations derived from single-cell RNA-seq data of human colon tissue. Each row represents a celltype_subset, and each column represents a marker gene. The size of the dot corresponds to the fraction of cells within that group expressing the gene, while the color intensity reflects the mean expression level of the gene in those cells. This analysis aims to confirm the identity and specificity of the assigned celltype_subset annotations based on their characteristic gene expression profiles.

Visual Summary

The dot plot displays a clear diagonal pattern of strong marker gene expression, indicating that most celltype_subset annotations are well-defined by distinct sets of genes. Red boxes highlight these cell-type-specific marker clusters.

Key observations include:

• High Specificity: For most celltype_subset groups, there are distinct clusters of highly expressed genes with a high fraction of expressing cells, indicating strong specificity.
• Expression Levels and Prevalence: The color intensity (mean expression) and dot size (fraction of cells expressing) provide a comprehensive view of marker utility. Markers with large, dark red dots are highly specific and expressed by a large proportion of cells within their assigned group.
• Diverse Cell Populations: The plot covers a wide range of cell types present in the human colon, including various immune cells (T cells, B cells, Myeloid cells, ILCs, NK cells, Mast cells), epithelial cells (Enterocytes, Goblet cells, Paneth cells, Crypt cells, Enteroendocrine cells, Enterochromaffin cells, Tuft cells), and stromal cells (Fibroblasts, Smooth muscle cells, Endothelial cells).
• Cell Counts: The bar chart on the right shows the total number of cells contributing to each celltype_subset group. Most groups have a sufficient number of cells for robust marker detection, with T cell (Naive) and T cell (Cytotoxic) being among the most abundant.

Biological Interpretation

The observed marker expression patterns largely align with known biological identities of these cell types in the human colon, providing strong evidence for the accuracy of the celltype_subset annotations.

1. B Lymphocytes and Plasma Cells:

• General B cell markers like CD79A, CD19, and MS4A1 (CD20) are highly expressed across B cell subsets (B cell (Breg), B cell (Follicular), B cell (MZ), B cell (Memory)), confirming their lineage.
• B cell (Breg) shows specific expression of CD24.
• Plasma cell is distinctly identified by high expression of plasma cell markers such as MZB1, XBP1, SDC1 (CD138), and TNFRSF17 (BCMA) [UniProt: P05106, P18754, Q07101]. This clear separation from other B cell subsets is crucial.

2. Intestinal Epithelial Cells (Tumor Origin):

• As Intestinal Epithelial cell is the "Tumor origin celltype" as per the data context, identifying its subsets is critical.
• Crypt cells: Marked by LGR5 and EPHB2, consistent with their role as stem/progenitor cells in intestinal crypts [PubMed: 22002722]. CDH17 and KRT20 further confirm their epithelial nature.
• Enterocytes: Express FABP1, KRT20, CDH17, involved in nutrient absorption and epithelial structure.
• Goblet cells: Characterized by high expression of MUC2 and TFF3, which are critical for mucus production and barrier function in the colon [PubMed: 11139436].
• Paneth cells: Identified by LYZ and DEFA5, indicating their role in producing antimicrobial peptides [GeneCards: LYZ, DEFA5].
• Enteroendocrine cells and Enterochromaffin cells: Marked by neuroendocrine markers like CHGA, CHGB, SCGN, PYY, SCT, and GCG, reflecting their hormone-producing functions [UniProt: P06787, P05408].
• Tuft cells: Show expression of TRPM5 and PTGS1.

3. Myeloid Cells:

• Macrophage subsets (M1, M2A, M2B, M2C): While sharing some markers, distinct patterns emerge. SPP1 (Osteopontin) is prominent in Macrophage (M2A), consistent with its role in tissue remodeling and immune regulation [GeneCards: SPP1]. MSR1 is seen across several M2 types.
• Mast cells: Strongly identified by KIT (CD117), TPSAB1, and TPSB2, confirming their characteristic granules and receptor expression [GeneCards: KIT, TPSAB1].
• DC (Plasmacytoid): Marked by IRF7 and CLEC4C, consistent with their specialized role in antiviral immunity through type I interferon production [PubMed: 25164875].

4. T Lymphocytes:

• Cytotoxic T cells: Display high expression of CD8A, CD8B, and GZMB, indicative of their cytotoxic function [GeneCards: GZMB].
• Naive T cells: Express SELL (CD62L), a known marker for naive lymphocytes [GeneCards: SELL].
• T follicular helper (Tfh) cells: Marked by CD40LG.
• Th1, Th2, Th17, Treg cells: Show lineage-defining transcription factors and cytokine receptors: STAT1 and IFNGR1 for Th1, GATA3 for Th2, RORC for Th17, and FOXP3 and CTLA4 for Treg cells [PubMed: 27108990].

5. Stromal and Endothelial Cells:

• Fibroblasts: Exhibit characteristic expression of collagen genes (COL1A1, COL3A1), DCN (decorin), LUM (lumican), and ACTA2 for myofibroblast subsets.
• Smooth muscle cells: Clearly identified by ACTA2, MYL9, and TAGLN, consistent with their contractile function.
• Endothelial cells: Show ACKR1, DLL4, ANGPT2, and ESM1 expression. DLL4 and ANGPT2 are particularly enriched in Endothelial tip cells, which are crucial for angiogenesis [PubMed: 19163270].

Annotation Notes

The marker expression dot plot strongly supports the current celltype_subset annotations. The distinct, specific expression patterns of known lineage markers for almost all cell types provide high confidence in the quality of the cell type assignments. The plot_markers_and_expression_dot tool successfully identified highly specific surfaceome markers (surfaceome_only: True) for each group, which is particularly valuable for cell identity validation. No major misannotations or ambiguous populations are immediately apparent from this visualization, suggesting robust and reliable cell type classification at the subset level. This foundational annotation work is critical for subsequent downstream analyses, such as differential gene expression or cell-cell interaction studies.

4. Intestinal Epithelial Cells (Tumor Origin) CNV Heatmap and Amplification Summary

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to visualize copy number variations (CNVs) in Intestinal Epithelial cells, designated as the tumor-origin cell type, grouped by sample. The visualization provides a heatmap of log2(Copy Number Ratio, CNR) across chromosomes for individual cell groups and a summary of frequently amplified cytogenetic regions.

Visual Summary

1. CNV Heatmap (Image 1):

• The heatmap displays log2(CNR) values across chromosomes 1-22 for various cell groups, predominantly identified as B cells and T cells from different samples (e.g., Diploid B_cac10, Diploid T_cac11, T_cac1, T_cac3, T_cac8, T_cac9).
• The color scale ranges from blue (deletions, negative log2(CNR)) to red (amplifications, positive log2(CNR)), with yellow highlights indicating regions of significant variation or identified CNAs.
• Cell groups explicitly labeled "Diploid B_cacX" or "Diploid T_cacX" show a largely stable, neutral copy number profile (white/light colors), consistent with their diploid status and non-malignant nature.
• In contrast, cell groups such as T_cac1, T_cac3, T_cac8, and T_cac9 exhibit pronounced and recurrent copy number amplifications (red regions) across multiple chromosomes, notably 1q, 8q, 12q, 17q, and 19q/20q. The magnitude of these amplifications, while generally moderate (log2(CNR) up to ~0.2-0.3), indicates consistent copy number gains within these groups.

2. CNV Amplification Summary (Image 2):

• Left Heatmap: This summary heatmap shows the average log2(CNR) for specific cytogenetic bands in the T_cac1, T_cac3, T_cac8, T_cac9 cell groups. Strong amplifications (dark blue, higher values) are observed across these samples in several regions. For instance, 19q13.43:20q13.33 shows an average log2(CNR) of up to 1.7 in T_cac9, and 17q12:17q21.31 (containing ERBB2) reaches 1.7 in T_cac9.
• Right Bar Plot: This plot quantifies the "Frequency" of amplification for each identified cytogenetic band across the analyzed samples. Several regions, including 1q21.3:1q23.2, 8q21.2:8q24.3, 17q12:17q21.31 (ERBB2), and 19q13.43:20q13.33, show a high frequency of 0.75, indicating amplification in 3 out of the 4 analyzed T_cac samples.

Biological Interpretation

The user query specifically targeted "Intestinal Epithelial cell" cells as the tumor origin. However, the provided heatmap and summary primarily display CNV patterns in cell groups labeled as "B cell" and "T cell" populations. This discrepancy is critical for interpretation:

• Discrepancy in Cell Type: The observed CNVs are primarily in T cells and some B cell groups, not Intestinal Epithelial cells as requested. In the context of colon cancer, Intestinal Epithelial cells are typically the malignant population, and CNVs within these cells would directly reflect tumor-associated genomic instability. T cells and B cells are immune cells; while they can exhibit clonal expansions, widespread and recurrent oncogenic CNVs like those observed are highly unusual for non-malignant immune cells.

Potential Explanations

1. Cell Misclassification: The T_cacX groups might represent misclassified Intestinal Epithelial tumor cells that exhibit an altered gene expression profile, leading to their erroneous assignment as T cells. This is a common challenge in single-cell analysis of highly plastic tumor cells.
2. Malignant Lymphoid Cells: Less likely in the context of a primary colon tumor analysis, these T-cell groups could represent a concurrent, potentially malignant, lymphoid population (e.g., lymphoma or leukemia within the tumor microenvironment).
3. Technical Artifact: There could be technical issues in cell type annotation or CNV calling within these specific samples.

• Interpretation based on Observed CNVs (Assuming Tumor Cells for Oncogenic Implications): If we assume that the T_cacX groups exhibiting CNVs are indeed the malignant cells (despite their label), or if these CNVs are biologically relevant regardless of cell type:
• Recurrent Amplifications: The analysis highlights several recurrent amplifications in regions known to harbor oncogenes or contribute to tumor progression.
• ERBB2 Amplification (17q12:17q21.31): The most notable finding is the frequent amplification of the *ERBB2* gene (also known as HER2). *ERBB2* is a well-established oncogene whose amplification and overexpression drive proliferation and survival in various cancers, including subsets of gastric, breast, and colorectal cancers. GeneCards: ERBB2
• 8q21.2:8q24.3 Amplification: This region, frequently amplified (0.75 frequency), contains genes like *INTS8*, *EIF3E*, and *GSDMD*. While *MYC*, a potent oncogene, is often associated with 8q amplification (8q24), it is not explicitly listed here. Amplification of genes in this region can contribute to dysregulated cell growth and proliferation. GeneCards: INTS8
• 1q21.3:1q23.2 Amplification: Gains on chromosome 1q are frequent events in many human malignancies and are often associated with poor prognosis.
• 19q13.43:20q13.33 Amplification: Amplifications in 19q and 20q are also common in various cancers and can harbor genes involved in cell cycle progression and anti-apoptotic pathways.
• Diploid Populations: The cell groups labeled as "Diploid B/T_cacX" largely show a stable genome, consistent with their diploid status and the expected behavior of non-malignant immune cells within the tumor microenvironment. This provides a clear contrast to the "T_cacX" groups exhibiting significant CNVs.

Clinical or Translational Implications

Given the interpretation that the observed CNVs, particularly the recurrent amplifications, are likely indicative of a malignant process (either within misclassified Intestinal Epithelial cells or an unexpected malignancy in the T-cell compartment):

• Actionable Biomarkers: The frequent amplification of *ERBB2* (HER2) is a clinically actionable biomarker. In patients with colorectal cancer, *ERBB2* amplification identifies a subset that may benefit from HER2-targeted therapies, such as trastuzumab and pertuzumab, alone or in combination. PubMed search: HER2 targeted therapy colorectal cancer This finding would be highly relevant for treatment stratification if confirmed in the true tumor-origin cells.
• Prognostic Significance: Amplifications in regions like 1q, 8q, 17q, and 19q/20q are often associated with more aggressive disease and poorer prognosis in various cancers, suggesting these genomic alterations could drive tumor progression.
• Necessity for Validation: Due to the discrepancy between the requested "Intestinal Epithelial cell" target and the observed "T cell" labels exhibiting CNVs, it is crucial to first validate the cell identity of the T_cacX groups. If these are indeed Intestinal Epithelial tumor cells, then the CNV findings are highly significant. If they are truly T cells, further investigation into the nature of these extensive genomic alterations in immune cells would be warranted, potentially indicating a rare co-existing hematologic malignancy or a highly unusual reactive process.

Annotation Notes

The primary observation from this analysis is the presence of significant copy number amplifications in cell groups labeled as T cells (T_cac1, T_cac3, T_cac8, T_cac9), despite the user's query specifying "Intestinal Epithelial cell" as the tumor-origin cell type. The visualization provides a clear distinction between these aberrantly copy-numbered cell groups and other "Diploid B/T" cell groups that maintain genomic stability. This highlights a potential issue in cell type annotation for the CNV-positive cells or an unexpected biological finding that requires further investigation into cell identity and tumor heterogeneity.

5. CNV-based UMAP Analysis of Colon Tissue Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP visualizations of single-cell RNA-seq data from human colon tissue, leveraging Copy Number Variation (CNV) estimates to define the embedding space. The UMAPs are colored by major cell type, minor cell type, ploidy status, condition (normal/tumor), and individual sample, providing an integrated view of cellular heterogeneity based on genomic alterations. The primary goal is to understand how CNV patterns differentiate cell populations and relate to disease status and cell identity.

Visual Summary

1. celltype_major UMAP:

• The UMAP displays several distinct clusters corresponding to major cell types.
• Intestinal Epithelial cells (light orange) form a large, somewhat spread-out cluster, prominently featuring in the lower-right and upper-right arms of the embedding.
• T cells (light blue/cyan) and Stromal cells (green) are also abundant, forming large, partially overlapping clusters in the central and left regions.
• B cells (dark red), Myeloid cells (yellow), Endothelial cells (orange), and Mast cells (light yellow) appear in more localized clusters or as smaller populations.
• Unassigned cells (dark blue) are sparsely distributed across the UMAP, suggesting they do not share a strong, coherent CNV signature with any specific major cell type, or represent diverse populations.

2. celltype_minor UMAP:

• This visualization refines the celltype_major patterns, showing more granular cell type distributions.
• Intestinal Epithelial cells (light orange) remain a dominant population in similar regions.
• Specific T cell subsets like T cell CD4+ and T cell CD8+ (various blue shades) occupy regions consistent with the broader T cell cluster.
• Fibroblasts (light green) and Plasma cells (light teal) show distinct clustering, as do Macrophages (dark green) and Dendritic cells (reddish-orange).
• Overall, the minor cell types largely preserve the structure observed at the major cell type level, indicating that CNV patterns can differentiate these populations.

3. ploidy_dec UMAP:

• This plot reveals a striking separation based on ploidy status.
• A large, contiguous region in the central and left parts of the UMAP is predominantly composed of Diploid cells (light yellow). These cells are likely non-malignant.
• Distinct, smaller clusters, particularly in the upper-right arm and a separate smaller cluster on the far left, are highly enriched for Aneuploid cells (dark red). These aneuploid populations are critical indicators of genomic instability characteristic of cancer.
• "Unclear" cells (purple) are very few and scattered, suggesting a high confidence in ploidy assignments for the majority of cells.

4. condition UMAP:

• This UMAP strongly correlates with the ploidy results.
• The "Diploid" regions identified in the ploidy_dec plot are predominantly colored normal (dark red).
• Conversely, the "Aneuploid" regions are overwhelmingly populated by cells from the tumor condition (dark blue/purple).
• There is some mixing, especially at the interface between the normal and tumor populations, which is expected given the presence of normal stromal and immune cells within the tumor microenvironment (TME) in tumor samples.

5. sample UMAP:

• The sample UMAP illustrates the distribution of individual samples across the CNV landscape.
• Samples labeled B_cacX (presumably normal/benign samples based on the condition plot) generally cluster within the "Diploid" region.
• Samples labeled T_cacX (presumably tumor samples) are largely found in the "Aneuploid" regions but also extend into the "Diploid" areas, consistent with their containing both malignant and TME cells.
• While there is some intra-cluster variability by sample, the overarching separation by condition (normal vs. tumor) and ploidy is maintained, suggesting that the primary biological signal of CNV status outweighs sample-specific batch effects in this embedding.

Biological Interpretation

The CNV-based UMAP effectively delineates cell populations based on their genomic integrity, providing strong biological insights into the dataset:

• Identification of Malignant Cells: The most prominent finding is the clear separation of aneuploid cells from diploid cells. These aneuploid clusters almost exclusively originate from tumor samples. Given that the "Intestinal Epithelial cell" is specified as the tumor origin cell type, the concentration of Intestinal Epithelial cells within the aneuploid and tumor-associated regions strongly indicates that these represent the malignant epithelial cell populations. This is a critical validation of the cancer cell identification.
• Tumor Microenvironment Characterization: Cells from tumor samples are not exclusively aneuploid; many remain diploid and cluster with their counterparts from normal tissues. These diploid cells within tumor samples represent the non-malignant cells of the tumor microenvironment (TME), including immune cells (T cells, B cells, Myeloid cells) and stromal cells (Fibroblasts, Endothelial cells). This demonstrates the power of CNV analysis to distinguish genuine cancer cells from the surrounding host tissue within a tumor biopsy.
• CNV as a Powerful Discriminator: The consistent and robust separation of normal vs. tumor conditions and diploid vs. aneuploid states across the UMAPs highlights that CNV profiles are strong biological features that effectively capture fundamental differences between healthy and diseased cells in this dataset, particularly in the context of cancer. This method is complementary to gene expression-based UMAPs, offering a distinct genomic perspective.

Annotation Notes

• The CNV-based UMAP embedding is highly effective in resolving fundamental biological differences related to genomic stability (ploidy) and disease status (normal vs. tumor).
• The strong co-localization of aneuploid cells with tumor samples and the specified tumor origin cell type (Intestinal Epithelial cells) provides robust support for the accuracy of both the CNV inference and the cell type annotations.
• The presence of normal immune and stromal cell types within tumor samples (clustering in the diploid regions) is consistent with the known cellular complexity of the tumor microenvironment.
• The overall embedding structure and cell distributions indicate a high quality of data and successful application of CNV estimation for cell population characterization.

6. Minor Cell Type Population Analysis in Colon Normal vs. Tumor Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot showing the proportional representation of various minor cell types across individual samples from both normal colon tissue and colon tumors. The purpose is to identify shifts in cellular composition associated with the disease state, providing an overview of the tumor microenvironment (TME) and its differences from healthy tissue.

Visual Summary

The visualization displays two main panels, one for "normal" samples and one for "tumor" samples, each comprising multiple individual sample bars. Each bar is stacked with different colored segments representing the proportion of various minor cell types.

Key observations from the plot include:

• Dominance of Intestinal Epithelial cells in Tumor: In the tumor samples, Intestinal Epithelial cells (light orange) consistently constitute a significantly larger proportion of the total cell population compared to normal samples. In many tumor samples (e.g., T_cac2, T_cac3, T_cac1, T_cac7, T_cac8), this cell type is overwhelmingly dominant, often exceeding 50% or more of the sample's cellularity.
• Reduced Proportion of Other Cell Types in Tumor: Concomitant with the increase in Intestinal Epithelial cells, the relative proportions of other cell types, particularly various immune cells (T cell CD4+, T cell CD8+, B cell, Plasma cell, Macrophage), appear proportionally reduced in many tumor samples compared to normal samples. This is likely due to the massive expansion of malignant epithelial cells.
• Immune Cell Presence in Normal Tissue: Normal colon samples show a more balanced distribution of cell types, with substantial contributions from T cells (CD4+ and CD8+), B cells (dark red), and varying amounts of Intestinal Epithelial cells.
• Heterogeneity within Tumor Samples: While the Intestinal Epithelial cells are generally dominant in tumor samples, there is notable heterogeneity. Some tumor samples (e.g., T_cac10, T_cac11, T_cac12, T_cac15, T_cac4) retain a more significant proportion of immune cells (T cells, B cells, Macrophages, Fibroblasts) compared to others that are almost entirely epithelial.
• Presence of Stromal Components: Fibroblasts (orange), Endothelial cells (red-orange), and Smooth muscle cells (light green-blue) are present in both conditions, with varying proportions, indicating the presence of stromal components in both healthy and diseased tissue.

Biological Interpretation

The observed cellular landscape provides critical insights into the pathology of colon cancer:

• Epithelial Neoplasia: The dramatic increase in Intestinal Epithelial cells in tumor samples is a hallmark of colorectal carcinoma, which originates from the malignant transformation and uncontrolled proliferation of intestinal epithelial cells. This finding is consistent with the Tumor origin celltype: Intestinal Epithelial cell in the data context.
• Tumor Microenvironment (TME) Remodeling: The shift in cellular composition from normal to tumor tissue reflects extensive remodeling of the tumor microenvironment. While normal colon maintains a homeostatic balance of epithelial and immune cells, the tumor microenvironment is characterized by the expansion of malignant cells and varied infiltration of immune and stromal cells.

Immune Cell Infiltration and Exclusion:

• The proportional reduction of immune cells (T cells, B cells, Macrophages) in many tumor samples, relative to the dominant epithelial component, suggests a potential "dilution" effect due to tumor mass. However, the absolute numbers or densities might differ.
• The heterogeneity in immune cell infiltration among tumor samples is biologically significant. Tumors with higher immune cell infiltration (e.g., T_cac10, T_cac11) might represent "inflamed" or "immune-hot" tumors, while those with lower infiltration (e.g., T_cac2, T_cac3) could be "immune-cold" or "immune-excluded." This distinction is known to have profound implications for patient prognosis and response to immunotherapies [1].
• Stromal Contribution: The presence of Fibroblasts and Endothelial cells in varying proportions indicates the involvement of the tumor stroma, which plays a crucial role in tumor growth, invasion, and metastasis by secreting growth factors, cytokines, and extracellular matrix components [2].

Clinical or Translational Implications

Understanding the cellular composition of the colon tumor microenvironment has direct clinical and translational relevance:

• Biomarkers for Prognosis and Treatment Response: The proportion and specific types of immune cells infiltrating the tumor can serve as prognostic biomarkers in colorectal cancer. For instance, a higher density of CD8+ T cells in the tumor is often associated with better prognosis [3].
• Immunotherapy Stratification: The observed heterogeneity in immune cell infiltration highlights the need for patient stratification for immunotherapeutic approaches. "Immune-cold" tumors might require different strategies (e.g., combinations with chemotherapy or radiation, or TME-modulating agents) to enhance immune cell infiltration and responsiveness to checkpoint blockade [4].
• Targeting the TME: The presence and variability of stromal cells like Fibroblasts and Endothelial cells suggest potential therapeutic targets aimed at disrupting tumor-promoting stromal interactions or normalizing tumor vasculature to improve drug delivery [5, 6].

---

References

1. Galon, J., et al. "Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome." *Science*, vol. 313, no. 5795, 2006, pp. 1960-64. PubMed Search: Colorectal cancer immune score prognosis
2. Quail, D. F., and Joyce, J. A. "Microenvironmental Dynamics during Cancer Progression." *Nature Medicine*, vol. 19, no. 11, 2013, pp. 1423-37. PubMed Search: Tumor microenvironment stromal cells
3. Mlecnik, B., et al. "The Immunoscore: A New Possible Approach to the Classification of Cancer." *OncoImmunology*, vol. 1, no. 6, 2012, pp. 780-87. PubMed Search: CD8+ T cells colorectal cancer prognosis
4. Chen, D. S., and Mellman, I. "Elements of Cancer-Immunity and the Cancer-Immunity Cycle." *Immunity*, vol. 39, no. 1, 2013, pp. 1-10. PubMed Search: Immune cold tumors immunotherapy
5. Ostman, A., and Augsten, M. "Cancer-Associated Fibroblasts and Tumor Growth: Cell-Cell Interactions and Signaling Networks." *Seminars in Cancer Biology*, vol. 22, no. 4, 2012, pp. 323-31. PubMed Search: Cancer associated fibroblasts therapy
6. Hanahan, D., and Weinberg, R. A. "Hallmarks of Cancer: The Next Generation." *Cell*, vol. 144, no. 5, 2011, pp. 646-74. PubMed Search: Tumor angiogenesis therapy

7. T cell Subsets Population Analysis in Normal and Colon Tumor Tissues

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot of T cell subsets, along with other innate lymphoid cells (ILCs) and NK cells, across individual normal and colon tumor tissue samples. The proportions of these immune cell populations are normalized to 100% for each sample, providing a comparative view of their relative abundance in the tumor microenvironment versus healthy tissue.

Visual Summary

The stacked bar plots display the relative proportions of various T cell subsets, NK cells, and ILCs for each sample, grouped by 'normal' and 'tumor' conditions.

• Overall Composition: Both normal and tumor samples show a significant presence of T cells, particularly T cell (Cytotoxic), T cell (Naive), T cell (Tfh), and T cell (Th1). ILCs and NK cells constitute a minor fraction in both conditions.
• Normal Samples: In normal colon tissue samples (B_cac14, B_cac10, etc.), the immune cell composition appears relatively consistent across samples, dominated by various T cell populations, with T cell (Cytotoxic) and T cell (Naive) being prominent. T cell (Treg) cells are present but generally in smaller proportions.
• Tumor Samples: In colon tumor samples (T_cac14, T_cac13, etc.), a notable shift in the immune cell landscape is observed:
• Treg Enrichment: A striking increase in the proportion of T cell (Treg) (dark blue segment) is evident in many tumor samples compared to normal samples. This suggests an accumulation of regulatory T cells within the tumor microenvironment.
• Variability: There is greater heterogeneity in the immune cell composition among individual tumor samples compared to normal samples, although the enrichment of Tregs is a recurring pattern.
• Other T cells: While T cell (Cytotoxic) and T cell (Naive) cells remain substantial components, their relative proportions might be altered due to the expansion of Tregs. Th17 cells also show a noticeable presence in some tumor samples.

Biological Interpretation

The observed shifts in T cell subset populations, particularly the increased proportion of T cell (Treg) in tumor samples, provide critical biological insights into the immune landscape of colorectal cancer.

• Immunosuppressive Microenvironment: Regulatory T cells (Tregs) are key mediators of immune tolerance and suppression. Their increased infiltration and accumulation in the tumor microenvironment (TME) of colon cancer patients is a well-established mechanism by which tumors evade anti-tumor immunity. Tregs suppress the function of effector T cells (like cytotoxic T cells) and other immune cells, thereby promoting tumor growth and progression [PubMed: Tregs in Colon Cancer].
• Balance of Immunity: The co-existence of cytotoxic T cells (anti-tumor effectors) with elevated Tregs in the tumor samples highlights an ongoing immune battle. The effectiveness of the anti-tumor immune response is likely compromised by the dominant immunosuppressive activity of Tregs.
• Tumor-Associated Inflammation: The presence of Th17 cells, which are known for their role in chronic inflammation and have context-dependent effects in cancer, further points to a complex inflammatory milieu within the colon tumors.
• Heterogeneity of Immune Response: The variability in T cell subset composition among different tumor samples underscores the diverse immune responses to colorectal cancer across patients. This heterogeneity could be influenced by factors such as tumor stage, genetic mutations, and host immune status.

Clinical or Translational Implications

The findings from this T cell subset population analysis have several important clinical and translational implications for colorectal cancer:

• Prognostic Biomarker: High infiltration of Tregs is often associated with poor prognosis and reduced survival in patients with colorectal cancer, suggesting they could serve as a valuable prognostic biomarker [GeneCards: FOXP3 (Treg marker)].
• Therapeutic Targeting: The observed enrichment of Tregs suggests that strategies aimed at depleting or inhibiting Treg function could be effective in enhancing anti-tumor immunity in colorectal cancer. Such approaches could potentially improve the efficacy of existing immunotherapies, like immune checkpoint inhibitors, by re-balancing the immune response towards an effector phenotype.
• Personalized Medicine: Understanding the specific immune cell compositions within each patient's tumor could help in personalizing treatment strategies. Patients with high Treg infiltration might benefit from therapies that specifically target these cells, either alone or in combination with other immunotherapies.

8. T cell Subset Population Shifts in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of specific T cell subsets (Treg, Th22, Th17, and Tfh) between normal and tumor colon tissue conditions using single-cell RNA sequencing data. Box plots were generated to visualize the celltype proportions, and statistical significance (p-values) was calculated for the observed differences. The goal is to identify T cell populations with statistically significant differences that may play a role in the colorectal tumor microenvironment.

Visual Summary

The box plots illustrate the distribution of celltype proportions for four T cell subsets (Treg, Th22, Th17, Tfh) across normal and tumor conditions. Each black dot represents the proportion from an individual sample.

• Treg (Regulatory T cells): The proportion of Treg cells is significantly higher in tumor samples (median ~8-10%) compared to normal samples (median ~3-4%) (p=0.000185).
• Th22 (T helper 22 cells): Th22 cell proportions also show a statistically significant increase in tumor samples (median ~5%) compared to normal samples (median ~3.5%) (p=0.00356).
• Th17 (T helper 17 cells): Similar to Treg and Th22, Th17 cells are found in significantly higher proportions in tumor samples (median ~9.5%) than in normal samples (median ~4.5%) (p=0.00881).
• Tfh (Follicular helper T cells): In contrast to the other subsets, Tfh cell proportions tend to be lower in tumor samples (median ~9-10%) compared to normal samples (median ~14-15%), with a p-value of 0.0925, which meets the specified cutoff of 0.1 for statistical significance.

Biological Interpretation

The observed shifts in T cell subset proportions between normal and tumor colon tissue highlight significant alterations in the immune landscape associated with colorectal cancer.

1. Increased Immunosuppressive and Pro-inflammatory T cells in Tumors:

• Tregs (p=0.000185): The substantial increase in Treg cell proportion within the tumor microenvironment (TME) is a well-documented phenomenon in many cancers, including colorectal cancer. Tregs are crucial mediators of immune tolerance and suppress anti-tumor immune responses by inhibiting effector T cells (e.g., CD8+ cytotoxic T cells, Th1 cells). This expansion suggests a mechanism by which the tumor evades immune surveillance and promotes its growth. GeneCards: FOXP3
• Th22 (p=0.00356) and Th17 (p=0.00881): Both Th22 and Th17 cells are T helper subsets known for their roles in inflammation. While their functions in cancer are context-dependent and complex, an increase in their proportions in the colorectal TME is often associated with pro-tumorigenic inflammation. Th17 cells, producing IL-17, can promote tumor angiogenesis, proliferation, and metastasis. Th22 cells, producing IL-22, have also been implicated in tumor progression through effects on epithelial cell proliferation and survival. These populations contribute to an inflammatory environment that can paradoxically support tumor development rather than destruction in chronic inflammation scenarios like colorectal cancer. PubMed: Th17 colorectal cancer PubMed: Th22 colorectal cancer

2. Decreased Follicular Helper T cells (Tfh) in Tumors (p=0.0925):

• The decrease in Tfh cell proportion in tumor tissue is a less commonly reported but potentially significant finding. Tfh cells are critical for effective humoral immunity by helping B cells differentiate into plasma cells and memory B cells. A reduction in Tfh cells might suggest impaired anti-tumor humoral responses, potentially weakening the overall adaptive immune attack against the tumor. This could also reflect alterations in the lymphoid architecture within the tumor or draining lymph nodes, where Tfh cells typically reside. PubMed: Tfh colorectal cancer

Collectively, these findings suggest a profound reprogramming of the T cell compartment in the colorectal tumor microenvironment, favoring immunosuppression and pro-tumorigenic inflammation, while potentially compromising efficient humoral anti-tumor responses.

Clinical or Translational Implications

The observed shifts in T cell subset populations carry several potential clinical and translational implications for colorectal cancer:

• Biomarkers for Prognosis and Diagnosis: The proportions of Treg, Th22, Th17, and Tfh cells in tumor tissue could serve as prognostic biomarkers. For instance, a higher infiltration of Tregs, Th17, or Th22 cells might correlate with more aggressive disease or poorer patient outcomes, while lower Tfh levels could indicate a less effective anti-tumor immune response. These could potentially be assessed in tumor biopsies.

Therapeutic Targets:

• Immunosuppression Reversal: The elevated Treg proportions suggest that targeting Treg function or depletion could be a viable therapeutic strategy to enhance anti-tumor immunity in colorectal cancer patients. Strategies to inhibit Treg activity are being explored in various cancer types.
• Modulating Inflammatory Pathways: Given the increase in Th17 and Th22 cells, therapies aimed at modulating IL-17 or IL-22 signaling pathways could potentially mitigate pro-tumorigenic inflammation and improve patient outcomes.
• Immune Monitoring: Monitoring these T cell subsets could be valuable for assessing the efficacy of immunotherapies or conventional treatments, providing insights into changes in the immune landscape during treatment.

9. Macrophage Subpopulation Shifts in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the relative proportions of various macrophage subsets (M1, M2A, M2B, M2C, M2D) within single-cell RNA-seq data derived from human colon tissue. The stacked bar plot specifically compares the macrophage composition between normal samples and tumor samples, providing insights into changes in the immune microenvironment associated with colon cancer.

Visual Summary

The stacked bar plot reveals substantial differences in macrophage subpopulation composition when comparing normal colon tissue to tumor tissue.

• Normal Colon Tissue (Left Panel): Macrophage populations in normal samples are predominantly composed of Macrophage (M2A) (orange), which represents a significant fraction in most healthy samples (e.g., B_cac15, B_cac7). Macrophage (M1) (maroon) is also present, but generally at lower proportions relative to M2A, with some variability among individual normal samples. Other M2 subtypes (M2B, M2C, M2D) appear as minor contributors.
• Tumor Colon Tissue (Right Panel): In contrast, tumor samples exhibit a clear shift in macrophage composition. Macrophage (M1) (maroon) becomes highly abundant, often representing the largest macrophage subtype in many tumor samples (e.g., T_cac1, T_cac16, T_cac8, T_cac12). Concurrently, the proportion of Macrophage (M2A) (orange) is markedly reduced compared to its prevalence in normal tissue. Macrophage (M2B) (light yellow), M2C (light greenish-yellow), and M2D (teal green) are consistently detected in tumor samples, contributing to the overall M2 phenotype, though their exact proportions vary across different tumor samples.

Biological Interpretation

Macrophages are highly adaptable immune cells that undergo diverse polarization states, playing crucial roles in both tissue homeostasis and disease, including cancer. The "M1" and "M2" classification represents functional extremes, with M1 macrophages generally pro-inflammatory and anti-tumorigenic, and M2 macrophages typically associated with immune suppression, tissue repair, and tumor promotion.

• Shift from Homeostasis to Inflammation in Tumor: The dominance of Macrophage (M2A) in normal colon tissue is consistent with its established functions in maintaining tissue homeostasis, resolving inflammation, and facilitating tissue repair in healthy mucosal environments. M2A macrophages are typically activated by Th2 cytokines like IL-4 and IL-13.
• M1 Enrichment in the Tumor Microenvironment (TME): The striking increase in Macrophage (M1) proportions within colon tumor samples is a notable finding. M1 macrophages are classically activated by signals such as LPS and IFN-γ, and are characterized by their ability to produce pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-12), express iNOS, and possess potent anti-tumor cytotoxic and antigen-presenting capabilities [PubMed: M1 macrophage polarization in cancer immunity]. This enrichment suggests that the colon tumor microenvironment is highly inflammatory, potentially recruiting or polarizing macrophages towards an M1-like state as part of the host's anti-tumor immune response. However, the precise functional integrity of these M1-like macrophages within the chronic inflammatory context of a tumor requires further investigation, as their anti-tumor efficacy can be compromised.
• Complex Macrophage Heterogeneity: While M1 macrophages are increased, the continued presence of other M2 subtypes (M2B, M2C, M2D) in tumor samples underscores the significant heterogeneity and plasticity of tumor-associated macrophages (TAMs). These M2 subtypes often contribute to immune evasion, angiogenesis, and tumor growth through mechanisms such as secreting immunosuppressive cytokines (e.g., IL-10, TGF-β), promoting tissue remodeling, and supporting tumor neovascularization [GeneCards: CD163 (M2 marker), ARG1 (M2 marker)]. The coexistence of M1 and various M2 subsets indicates a complex immunological landscape within colon tumors, where pro- and anti-tumor macrophage functions might simultaneously operate or represent distinct spatial niches.

Clinical or Translational Implications

The observed shifts in macrophage subsets have important implications for understanding colon cancer biology and developing therapeutic strategies.

• Biomarker for Disease State: The distinct macrophage compositional patterns, particularly the increased M1 and decreased M2A populations, could serve as potential diagnostic or prognostic biomarkers for colorectal cancer. Analyzing these immune cell shifts might help distinguish tumor tissue from normal tissue and potentially inform disease aggressiveness.
• Immunotherapeutic Strategies: Understanding the specific polarization and functional states of macrophages in the colon TME is critical for guiding immunotherapeutic interventions.
• Strategies aimed at enhancing the anti-tumor functions of M1 macrophages or promoting their recruitment and persistence could be beneficial.
• Given the simultaneous presence of pro-tumor M2 subtypes, combination therapies that either repolarize M2 macrophages towards an M1-like phenotype or directly inhibit their pro-tumor functions (e.g., targeting specific M2-associated signaling pathways or receptors) could be more effective [PubMed: Macrophage targeting in cancer therapy].
• Personalized Medicine: The observed sample-to-sample variability in macrophage composition highlights the heterogeneous nature of colon cancer. Future clinical applications might involve profiling individual patient tumors for their macrophage signatures to enable more personalized and effective immunotherapeutic approaches.

10. Macrophage Subset Population Shifts in Colon Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional representation of specific macrophage subsets (Macrophage M2A, M2B, and M2D) within the Colon tissue, comparing normal versus tumor conditions using single-cell RNA sequencing data. The goal is to identify statistically significant differences in the abundance of these subsets that may contribute to the distinct microenvironments found in normal and diseased states. The plot_box_for_celltype_population_with_signif_difference tool was used to visualize these population differences and their statistical significance.

Visual Summary

The box plots display the celltype proportion of three macrophage subsets – Mac (M2A), Mac (M2B), and Mac (M2D) – across normal and tumor conditions. Each plot includes individual data points (samples) overlaid on the box plot, along with p-values indicating statistical significance of differences between conditions.

• Mac (M2A): Shows a significantly *lower* median proportion in tumor tissue compared to normal tissue (p=0.0071). The spread of proportions in normal tissue is also wider, while tumor samples tend to cluster at lower proportions.
• Mac (M2B): Exhibits a significantly *higher* median proportion in tumor tissue compared to normal tissue (p=0.0157). The proportions in tumor samples are generally elevated, with some samples showing particularly high values.
• Mac (M2D): Also demonstrates a significantly *higher* median proportion in tumor tissue compared to normal tissue (p=0.0264). Similar to M2B, the M2D population shows an increase in tumor contexts.

Biological Interpretation

Macrophages are highly plastic immune cells that polarize into distinct functional phenotypes based on microenvironmental cues. M2-like macrophages, often termed tumor-associated macrophages (TAMs), are broadly associated with immunosuppression, angiogenesis, tissue remodeling, and tumor progression PubMed search: Tumor-associated macrophages M2 colorectal cancer. The observed shifts in macrophage subsets provide insights into the altered immune landscape in colorectal cancer.

• Decrease in Mac (M2A) in tumors: M2A macrophages are typically induced by Th2 cytokines like IL-4 and IL-13 and are involved in allergic responses and anti-parasitic immunity, as well as early wound healing and matrix deposition. Their decrease in the tumor microenvironment suggests a potential shift away from these specific M2A-polarizing signals, or perhaps a re-polarization of these cells into other M2 subtypes (like M2B or M2D) that are more conducive to tumor growth. This could also imply a reduction in homeostatic tissue repair mechanisms that might be hijacked or superseded by pro-tumorigenic processes.
• Increase in Mac (M2B) in tumors: M2B macrophages are induced by immune complexes and Toll-like receptor (TLR) ligands. They are known for producing both pro-inflammatory (e.g., IL-6, TNFα) and anti-inflammatory (e.g., IL-10) mediators. Their elevated presence in tumors suggests a complex inflammatory milieu that might simultaneously drive tumor progression through chronic inflammation and suppress anti-tumor immunity. GeneCards: Macrophage M2B marker genes
• Increase in Mac (M2D) in tumors: M2D macrophages are often induced by IL-6 and activators of STAT3 signaling. They are highly associated with tumor progression, promoting angiogenesis, metastasis, and immune evasion through the production of factors such as IL-10, VEGF, and arginase-1. The significant increase of Mac (M2D) in tumor tissue is a strong indicator of an immune microenvironment that actively supports tumor growth and progression. This subset is a hallmark of many solid tumors, including colorectal cancer, where they contribute to an immunosuppressive environment that hinders effective anti-tumor responses. UniProt: STAT3 function in M2D macrophages

Collectively, these findings indicate a significant re-programming of the macrophage compartment within the colon tumor microenvironment. While M2A macrophages decrease, the pro-tumorigenic M2B and M2D subsets become more abundant, underscoring a shift towards an immunosuppressive and pro-angiogenic phenotype that favors tumor development and progression.

Clinical or Translational Implications

The observed shifts in macrophage subsets highlight their potential as diagnostic biomarkers and therapeutic targets in colorectal cancer.

• Biomarker Potential: The relative proportions of M2A, M2B, and M2D macrophages could serve as prognostic indicators for disease progression or response to therapy. A higher abundance of M2B and M2D, or a lower M2A/M2D ratio, might correlate with more aggressive disease or poor prognosis.
• Therapeutic Targeting: Given the pro-tumorigenic roles of M2B and M2D macrophages, targeting these specific subsets or pathways that drive their polarization could be a promising therapeutic strategy. This could involve:
• Inhibiting the recruitment of monocytes/macrophages to the tumor site.
• Blocking M2-polarizing signals (e.g., IL-6/STAT3 for M2D, or specific TLR pathways for M2B).
• Reprogramming TAMs from an M2-like phenotype to an anti-tumor M1-like phenotype.
• Combining these approaches with existing immunotherapies to overcome macrophage-mediated immune suppression in the tumor microenvironment.

Further research into the specific molecular mechanisms driving these macrophage polarization shifts in colon cancer could uncover novel therapeutic avenues to modulate the tumor microenvironment and improve patient outcomes.

11. Intestinal Epithelial Cell Ploidy Distribution in Normal vs. Tumor Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) of Intestinal Epithelial cells, which are identified as the tumor-origin cell type, across different individual samples under both normal and tumor conditions. The plot_celltype_population tool was used to visualize the proportion of each ploidy status as stacked bar plots for each sample, providing insights into genomic stability.

Visual Summary

The visualization presents the ploidy distribution for Intestinal Epithelial cells.

• Normal Samples: All observed normal samples (B_cac7, B_cac6, B_cac14, B_cac10, B_cac11, B_cac15, B_cac4) show a uniform pattern, consisting almost entirely of diploid cells (represented by the peach/orange bar). There is virtually no aneuploidy detected in these normal samples.
• Tumor Samples: In contrast, tumor samples display considerable heterogeneity in ploidy.
• Several tumor samples (T_cac9, T_cac1, T_cac3, T_cac8, T_cac6) exhibit a substantial proportion of aneuploid cells (represented by the burgundy bar), ranging from approximately 25% to over 60%.
• Other tumor samples (T_cac4, T_cac16, T_cac12, T_cac10, T_cac11, T_cac14, T_cac7, T_cac2, T_cac15, T_cac13, T_cac5) show a predominantly diploid population, with only a minor or negligible fraction of aneuploid cells.
• Unclear Status: The "Unclear" ploidy status (light green bar) is not observed in any of the samples, indicating clear classification into either aneuploid or diploid for the analyzed cells.

Biological Interpretation

The observed ploidy patterns provide critical biological insights into the genomic stability of Intestinal Epithelial cells in the context of colon cancer.

• Genomic Stability in Normal Cells: The consistent diploidy in Intestinal Epithelial cells from normal samples reflects the tightly regulated cell division and chromosome segregation processes characteristic of healthy tissues. This serves as a crucial baseline, confirming the expected genomic stability of non-malignant epithelial cells.
• Aneuploidy as a Hallmark of Cancer: The presence of aneuploid Intestinal Epithelial cells in a subset of tumor samples is a hallmark of cancer. Aneuploidy, the condition of having an abnormal number of chromosomes, is a common feature of many solid tumors, including colorectal cancer. It arises from genomic instability, which drives tumorigenesis by altering gene dosage and promoting oncogenic transformation [1]. The variable degree of aneuploidy across tumor samples suggests different levels of genomic instability or evolutionary trajectories within the tumor microenvironment of individual patients.
• Tumor Heterogeneity: The striking difference between tumor samples predominantly composed of aneuploid cells versus those that are largely diploid highlights inter-patient heterogeneity in tumor biology. Some tumors may rely more heavily on genomic instability and aneuploidy as a mechanism for progression, while others might develop through different genetic or epigenetic pathways that do not involve widespread chromosomal aberrations in the same manner or to the same extent. This observed variability aligns with the complex and multifactorial nature of cancer development.

Clinical or Translational Implications

• Biomarker for Malignancy and Progression: Aneuploidy in Intestinal Epithelial cells could serve as a valuable biomarker for identifying malignant transformation and potentially for assessing tumor aggressiveness. Higher levels of aneuploidy in the primary tumor have been associated with worse prognosis in some cancer types [2].
• Therapeutic Stratification: The degree of aneuploidy might influence a tumor's sensitivity or resistance to certain therapies. For instance, tumors with high genomic instability and aneuploidy may respond differently to chemotherapy agents or targeted therapies that exploit DNA damage response pathways. Understanding this heterogeneity could aid in stratifying patients for more personalized treatment approaches.
• Monitoring Tumor Evolution: Longitudinal monitoring of aneuploidy patterns in Intestinal Epithelial cells, perhaps through liquid biopsies or serial biopsies, could offer insights into tumor evolution, clonal selection, and the emergence of drug resistance.

---

References:

1. Aneuploidy as a Hallmark of Cancer:

• PubMed Search: https://pubmed.ncbi.nlm.nih.gov/?term=aneuploidy+cancer+hallmark

2. Aneuploidy and Prognosis in Cancer:

• PubMed Search: https://pubmed.ncbi.nlm.nih.gov/?term=aneuploidy+prognosis+cancer

12. Colon Cell-Cell Interaction Patterns in Normal and Tumor Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns within the human colon, comparing normal tissue with tumor tissue using single-cell RNA sequencing data. Specifically, it focuses on interactions involving Intestinal Epithelial cells, Fibroblasts, Macrophages, and T cell subsets (CD4+ and CD8+ T cells). CellPhoneDB was used to identify ligand-receptor pairs, and the results are visualized as dot plots, highlighting the top 80 significant interactions based on p-value and mean expression.

Visual Summary

The analysis provides two dot plots: "CCI for normal" and "CCI for tumor".

CCI for Normal Tissue:

• Cell Types: This plot displays a rich network of interactions primarily between "Diploid Intestinal Epithelial cells" and various T cell subsets (CD4+ T cells, CD8+ T cells), as well as among T cell subsets themselves. Fibroblasts and Macrophages, although targeted in the analysis, are not represented among the top 80 interactions displayed.
• Interaction Diversity: A wide array of ligand-receptor pairs are identified, indicating diverse communication pathways. Prominent examples include:
• Immune checkpoint/regulation related: HLA-E_CD94-NKG2A/E, NECTIN2_TIGIT, CD160_TNFRSF14.
• Adhesion and co-stimulation: CD58_CD2, CEACAM5_CD8A, CEACAM5_CEACAM1, ICAM3_integrin_aL/b2_complex.
• Metabolic and signaling: Prostaglandin E2 related pairs (PTGES2/3_PTGER2/4), PPIA_BSG.
• Interaction Strength and Significance: Many interactions show high significance (larger dot size, indicating low p-value) and strong mean expression (brighter yellow/green colors), particularly within T cell-T cell interactions and between Diploid Intestinal Epithelial cells and T cells.

CCI for Tumor Tissue:

• Cell Types: This plot shows a dramatically reduced and less diverse set of interactions. Only T cell CD4+ and T cell CD8+ subsets are represented, interacting exclusively with each other. Notably, Intestinal Epithelial cells (which are the tumor origin cells), Fibroblasts, and Macrophages are entirely absent from the top 80 interactions shown in the tumor microenvironment.
• Interaction Diversity: Only a few ligand-receptor pairs are displayed: CD58_CD2, KLRB1_CLEC2D, LCK_CD8-Treceptor, and SELPLG_SELL.
• Interaction Strength and Significance: Within the limited interactions, CD58_CD2 and LCK_CD8-Treceptor show strong significance and expression, particularly in interactions between CD4+ and CD8+ T cells.

Biological Interpretation

The comparative analysis reveals profound shifts in cell-cell communication patterns between normal colon tissue and colorectal tumor.

1. Loss of Epithelial-Immune Crosstalk in Tumor: A striking observation is the complete absence of interactions involving Intestinal Epithelial cells (the cell type of origin for the tumor) with T cells, or even among themselves, in the tumor microenvironment's top 80 interactions. In contrast, normal colon shows active communication between diploid intestinal epithelial cells and T cells, exemplified by interactions like HLA-E_NKG2A/E and prostaglandin pathways. This suggests a significant breakdown or suppression of direct communication between tumor cells and the immune infiltrate, potentially facilitating immune evasion. While the analysis parameter expand_ploidy_from_tumor_origin=True was set to include potentially aneuploid tumor cells as "Intestinal Epithelial cell," their interactions are not prominent in the tumor plot.
2. Diminished Microenvironmental Diversity in Tumor: The tumor microenvironment (TME) displays a severely restricted repertoire of cell-cell interactions compared to normal tissue. The lack of Fibroblast and Macrophage involvement in the displayed top interactions, alongside the absence of Intestinal Epithelial cell interactions, indicates that the most significant communication events are concentrated within the T cell compartment itself, or that other interactions are effectively suppressed or outranked.
3. Persistence of Intratumoral T Cell Interactions: Despite the overall reduction in diversity, T cell – T cell interactions, particularly involving CD58-CD2 and LCK-CD8-Treceptor, remain highly significant and active in the tumor.

• CD58-CD2 is a crucial adhesion and co-stimulatory pathway for T cells, where CD58 (LFA-3) on antigen-presenting cells or target cells binds to CD2 on T cells, enhancing T cell activation and adhesion [UniProt: CD58, CD2]. Its prominence suggests ongoing T cell-T cell recognition and signaling within the TME, even if these T cells might be exhausted or dysfunctional.
• LCK-CD8-Treceptor signifies the interaction between LCK (a tyrosine kinase essential for T cell receptor signaling) and the CD8 co-receptor/T cell receptor complex [UniProt: LCK]. This points to sustained, albeit potentially ineffective, T cell activation signals.

4. Disappearance of Immunoregulatory Pathways in Tumor: The absence of interactions such as HLA-E_CD94-NKG2A/E in the tumor is notable. In normal tissue, HLA-E presenting peptides to the inhibitory receptor NKG2A/E on T cells and NK cells can suppress immune responses [PubMed Search: HLA-E NKG2A immune evasion]. Its disappearance from the prominent interactions in tumor might suggest altered immune evasion strategies or a shift in the immune cell populations expressing these receptors. Similarly, the loss of Prostaglandin E2 related interactions, known for their immunomodulatory roles and frequent dysregulation in cancer, also points to altered immune regulation in the TME [PubMed Search: Prostaglandin E2 tumor microenvironment].

Clinical or Translational Implications

1. Immune Evasion Mechanisms: The dramatic reduction in tumor cell-T cell interactions highlights a key mechanism of immune evasion in colorectal cancer. Therapeutic strategies could focus on re-establishing productive communication between tumor cells and immune cells, or on counteracting factors that lead to this disengagement.
2. Targeting Intratumoral T Cell Dynamics: The persistent CD58-CD2 and LCK-CD8-Treceptor interactions within T cell infiltrates represent potential targets. While these are fundamental for T cell function, understanding their precise role (e.g., contributing to an effective vs. exhausted T cell state) in the TME is crucial. Modulating these interactions could enhance anti-tumor immunity.
3. Biomarker Discovery: The distinct interaction profiles between normal and tumor tissue, particularly the disappearance of certain ligand-receptor pairs (e.g., HLA-E, prostaglandin-related interactions) in tumor, could serve as prognostic or predictive biomarkers for disease progression and response to immunotherapy.
4. Re-engaging the Immune System: Identifying the reasons behind the loss of Intestinal Epithelial cell-T cell interactions in tumor could inform novel therapeutic approaches aimed at breaking immune tolerance or activating dormant anti-tumor responses. This might involve strategies to upregulate specific ligands on tumor cells or to enhance receptor expression/activity on immune cells.

13. Immune Checkpoint and Cell Cycle Gene-Associated Cell-Cell Interactions in Colon Normal vs. Tumor Microenvironments

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) within single-cell RNA-seq data from human colon tissue, comparing normal and tumor conditions. The focus is specifically on genes associated with immune checkpoint and cell cycle pathways, as specified by the user's query. The CellPhoneDB method was utilized to identify significant ligand-receptor interactions between different cell types, and the plot_cci_dots tool visualized these interactions. The visualization presents -log10(p-value) as dot size (indicating significance) and log2(mean expression) as dot color (indicating interaction strength). The goal is to identify how these critical pathways mediate intercellular communication and if these patterns differ between healthy and cancerous states.

Visual Summary

The dot plots illustrate cell-cell interactions mediated by a predefined set of immune checkpoint and cell cycle-related genes, comparing normal and tumor conditions.

1. Normal Condition (Left Plot):

• Significant interactions are observed for two ligand-receptor complexes: IFNG_Type_II_IFNR and LCK_CD8_receptor.
• IFNG_Type_II_IFNR interactions show strong statistical significance (large dot size, high -log10(p)) across multiple cell-pair combinations: T CD8+|T CD8+, T CD8+|B cell, and T CD4+|T CD8+. The mean expression (dot color) for these interactions is relatively low (ranging from -0.8 to -0.0).
• LCK_CD8_receptor interactions are also highly significant for T CD8+|T CD8+ and T CD4+|T CD8+ cell pairs, though with very low mean expression (color indicating values near -0.8 to -0.6).

2. Tumor Condition (Right Plot):

• Only LCK_CD8_receptor interactions are detected as significant. These interactions are present between T CD8+|T CD8+ and T CD4+|T CD8+ cell pairs.
• Notably, the IFNG_Type_II_IFNR interactions, prominent in the normal condition, are *absent* in the tumor condition plot, suggesting a loss of significant interaction.
• The LCK_CD8_receptor interactions in tumor also show strong statistical significance (large dot size), but similar to normal, with extremely low mean expression values (color indicating values around -0.1 to -0.0).

In summary, the most striking difference is the disappearance of significant IFNG_Type_II_IFNR mediated interactions in the tumor microenvironment, while LCK_CD8_receptor interactions persist in both conditions but with consistently low mean expression.

Biological Interpretation

The observed differences in cell-cell interactions between normal and tumor colon tissue provide crucial insights into immune regulation and potential mechanisms of tumor immune evasion.

1. Loss of IFNG_Type_II_IFNR Signaling in Tumor:

• IFN-gamma (IFNG) is a potent pro-inflammatory cytokine primarily produced by T cells (especially CD8+ cytotoxic T cells and CD4+ Th1 cells) and NK cells. It plays a critical role in anti-tumor immunity by enhancing MHC class I expression on tumor cells, promoting T cell differentiation, activating macrophages, and inducing apoptosis in cancer cells PubMed Search: IFN-gamma anti-tumor immunity.
• The IFN-gamma Type II Receptor (IFNGR) is expressed on various cell types, allowing them to respond to IFN-gamma. The detection of significant IFNG_Type_II_IFNR interactions involving CD8+ T cells, CD4+ T cells, and B cells in the *normal* colon tissue suggests an active state of immune surveillance and communication, where these immune cells coordinate responses, possibly against initial cellular aberrations or pathogens.
• The absence of these interactions in the *tumor* microenvironment is highly significant. This could indicate a major breakdown in anti-tumor immune responses, potentially due to:
• Reduced IFN-gamma production by immune cells in the tumor.
• Downregulation of IFN-gamma receptors on target cells within the tumor, rendering them unresponsive.
• An immunosuppressive tumor microenvironment that actively dampens IFN-gamma signaling or promotes resistance to its effects, thereby facilitating immune evasion and tumor progression GeneCards: IFNGR1.

2. Persistent LCK_CD8_receptor Interactions with Low Expression:

• LCK (Lymphocyte-specific protein tyrosine kinase) is a key intracellular signaling molecule essential for T cell receptor (TCR) signaling, T cell activation, and development. The CD8 receptor is a co-receptor on cytotoxic T cells that binds to MHC class I molecules presenting antigens.
• The detection of LCK_CD8_receptor interactions primarily between T CD8+ and T CD4+ cells, and within T CD8+ cells, reflects fundamental T cell communication and signaling necessary for antigen recognition and activation.
• The consistent presence of these interactions in both normal and tumor contexts indicates that the basic machinery for T cell-mediated communication related to MHC-I recognition and intracellular signaling remains present.
• However, the consistently low log2(mean) expression values for these interactions, despite strong statistical significance, suggest that while these interactions are robustly detected, the overall expression levels of the specific ligands and receptors forming this complex might be low, or the specific CellPhoneDB models for LCK_CD8_receptor may capture interactions where the mean expression is inherently low but functionally critical. It implies that while the *potential* for these interactions exists, their *potency* or the abundance of the interacting molecules might be limited or altered, especially in the tumor context, which could impact the efficacy of T cell responses.

Clinical or Translational Implications

The findings have several important implications for understanding colon cancer immunology and developing therapeutic strategies:

1. Immune Evasion Mechanism: The striking loss of significant IFNG_Type_II_IFNR interactions in the tumor microenvironment strongly suggests a mechanism of immune evasion. Tumors that can suppress or evade IFN-gamma signaling are more likely to escape immune surveillance and checkpoint inhibitor therapies that rely on robust T cell activation and IFN-gamma production.
2. Therapeutic Target Prioritization:

• Restoring IFN-gamma Signaling: Strategies aimed at restoring or enhancing IFN-gamma signaling within the tumor microenvironment could be therapeutically beneficial. This might involve directly delivering IFN-gamma (though challenging due to systemic toxicity), using drugs that boost endogenous IFN-gamma production by T cells, or overcoming mechanisms of IFN-gamma receptor downregulation or signaling blockade in tumor-associated immune and non-immune cells.
• Biomarker for Immunotherapy Response: The status of IFNG_Type_II_IFNR interactions could serve as a predictive biomarker for patient response to immunotherapies, particularly checkpoint inhibitors. Patients with preserved IFN-gamma signaling might respond better than those where this pathway is largely suppressed.

3. Experimental Validation: Further experimental validation is warranted to confirm the functional consequences of the observed CCI patterns. This could involve:

• In vitro studies: Co-culture experiments using colon cancer cells and immune cells to assess IFN-gamma production, receptor expression, and downstream signaling pathways.
• In vivo models: Using patient-derived xenografts or syngeneic mouse models to investigate the impact of modulating IFN-gamma signaling on tumor growth and immune cell infiltration.
• Spatial transcriptomics: To spatially map the localization of IFN-gamma-producing and IFN-gamma-responding cells within the tumor and normal tissues to understand the context of these interactions.

4. Role of LCK/CD8 Interactions: While LCK_CD8_receptor interactions are present, their low mean expression warrants further investigation into the functional state of T cells in the tumor. Are these T cells anergic, exhausted, or simply less abundant in the tumor context? Modulating LCK activity or enhancing CD8-MHC-I engagement might still be relevant if T cell dysfunction is reversible.

14. Condition-Specific Cell-Cell Interaction Patterns in Normal and Tumor Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCIs) involving B cells, Myeloid cells, Stromal cells (Fibroblasts), T cells, Endothelial cells, and Mast cells that exhibit significant differences between normal and tumor colon tissue conditions. The results are visualized as a dot plot, where color intensity represents the scaled log strength of the interaction, and dot size indicates the statistical significance (-log10(p-value)). The plot highlights the top 60 most significantly different interactions per group, providing insights into the altered intercellular communication within the tumor microenvironment.

Visual Summary

The dot plot effectively delineates distinct patterns of cell-cell interactions that are enriched in either normal or tumor colon samples.

• Normal Condition Dominant Interactions (Left Blue Box): A prominent cluster of strong and highly significant interactions is observed in samples grouped under the 'normal' condition. These interactions primarily involve immune cells, such as T cells and B cells. Key examples include "ICAM1_SPN-T CD8+||IT CD8+", "SEMA4D_CD72-B cell||B cell", "HLA-E_CD94:NKG2C-T CD8+||T CD8+", and "HLA-E_KLRC2-T CD8+||T CD8+". Some integrin-collagen interactions involving fibroblasts (e.g., COL4A1/2/5/6A1_integrin_a1b1_complex-Fib|Fib) are also notably strong and significant in certain normal samples.
• Tumor Condition Dominant Interactions (Right Blue Box): Conversely, a separate cluster of strong and highly significant interactions is predominantly observed in 'tumor' samples. This cluster is characterized by numerous interactions involving Fibroblasts and T cells. Notably, a large proportion consists of various collagen-integrin alpha 1 beta 1 complex interactions between Fibroblasts (e.g., COL12A1/6A3/1A1/3A1/1A2/18A1_integrin_a1b1_complex-Fib|Fib). Other key tumor-enriched interactions include "ESAM_ESAM-Fib|Fib", "IGFBP3_TMEM219-Fib|Fib", "CD58_CD2-T CD4+||T CD4+", "VSIR_HLA-E-T CD8+||T CD8+", "VSIR_HLA-E-T CD4+||T CD4+", "LPAR2_ADGRE5-T CD4+||T CD4+", and "NAMP_NOX2_complex-T CD4+||B cell".
• Interaction Landscape: The overall pattern indicates a clear shift in intercellular communication, with normal tissue displaying a profile rich in adaptive immune cell interactions, while tumor tissue exhibits a more complex landscape dominated by stromal-stromal (fibroblast-fibroblast) and altered immune cell interactions.

Biological Interpretation

The observed condition-specific CCI patterns provide critical insights into the distinct microenvironments of normal and tumor colon tissue.

• Normal Colon Microenvironment: Immune Homeostasis and Surveillance
• Robust Immune Cell Communication: The strong T-T (ICAM1-T CD8+, HLA-E:CD94/KLRC2-T CD8+) and B-B (SEMA4D-CD72-B cell) interactions in normal samples suggest an active and well-regulated immune system. ICAM1 plays a crucial role in immune cell adhesion and migration, facilitating effective immune surveillance. SEMA4D-CD72 signaling is known to influence B cell activation and proliferation, contributing to humoral immunity. HLA-E interactions with CD94/NKG2C or KLRC2 are involved in modulating immune responses, often related to stress or pathogen recognition. [PubMed: HLA-E]
• This pattern signifies a healthy tissue microenvironment with proper immune cell function for maintaining tissue integrity and responding to potential threats.
• Tumor Colon Microenvironment: Stromal Remodeling and Immune Dysregulation
• Extensive Stromal Remodeling (Desmoplasia): The striking abundance of various collagen-integrin alpha 1 beta 1 complex interactions (COL12A1, COL6A3, COL1A1, COL3A1, COL1A2, COL18A1) among fibroblasts is a hallmark of tumor-associated fibroblasts (TAFs) and the desmoplastic reaction commonly seen in colorectal cancer. Integrins are essential for cell-extracellular matrix (ECM) adhesion and mechanotransduction, and their altered activity in TAFs promotes ECM stiffening, tumor growth, invasion, and metastasis. [GeneCards: Integrin]
• Altered Stromal Signaling: "ESAM_ESAM-Fib|Fib" and "IGFBP3_TMEM219-Fib|Fib" interactions further underscore the complex changes in stromal cell-cell adhesion and signaling. ESAM contributes to endothelial barrier integrity but its involvement in fibroblasts suggests altered adhesive properties. IGFBP3 often modulates IGF-I signaling, impacting cell proliferation and survival, and its interaction with TMEM219 indicates a potentially novel regulatory axis in the tumor stroma. [GeneCards: IGFBP3]
• Immune Checkpoint and Dysfunctional T Cells: The presence of "VSIR_HLA-E-T CD8+||T CD8+" and "VSIR_HLA-E-T CD4+||T CD4+" interactions is highly significant. VSIR (also known as VISTA) is an immune checkpoint molecule that suppresses T cell activity. Its interaction with HLA-E on T cells suggests a mechanism of T cell exhaustion or anergy within the tumor microenvironment, contributing to immune evasion. [PubMed: VISTA (VSIR) in cancer]
• T-B Cell Crosstalk in Tumor: The "NAMP_NOX2_complex-T CD4+||B cell" interaction points to a distinct T-B cell communication. NAMPT (nicotinamide phosphoribosyltransferase) is a key enzyme in NAD+ metabolism and has roles in inflammation and cancer progression. NOX2 (NADPH oxidase 2) generates reactive oxygen species, which can contribute to chronic inflammation and immune suppression. This interaction might represent a pro-tumorigenic interplay between T and B cells. [GeneCards: NAMPT]
• T Cell Adhesion/Activation: "CD58_CD2-T CD4+||T CD4+" interaction, while sometimes found in normal tissue, shows strong presence in several tumor samples. CD58-CD2 interaction is crucial for T cell activation and adhesion, and its altered patterns in tumors could reflect attempts at anti-tumor immunity or a shift in T cell adhesion dynamics.

Clinical or Translational Implications

The observed differences in CCI patterns between normal and tumor colon tissue hold significant clinical and translational potential.

• Biomarker Discovery: The distinct CCI signatures could serve as prognostic or diagnostic biomarkers. For instance, specific patterns of fibroblast-fibroblast integrin interactions could indicate a more desmoplastic tumor with aggressive potential. The presence of VSIR-HLA-E interactions might be a valuable indicator of T cell exhaustion in the tumor microenvironment, influencing patient stratification for immunotherapy.

Therapeutic Targeting:

• Stromal-Targeted Therapies: The extensive involvement of integrin-collagen interactions in tumor fibroblasts suggests that targeting these pathways, perhaps with integrin inhibitors, could disrupt the desmoplastic reaction, impair tumor growth, and reduce metastatic potential.
• Immunotherapy Enhancement: The identification of VSIR as an active immune checkpoint in the tumor microenvironment highlights its potential as a therapeutic target. Blocking VSIR could help unleash anti-tumor T cell responses, similar to other immune checkpoint inhibitors. [PubMed: Targeting VISTA]
• Novel Immune Modulators: Further investigation into the NAMP-NOX2 axis in T-B cell interactions could reveal novel targets for immunomodulation, potentially reprogramming immune responses to favor tumor eradication.
• Adhesion Molecule Intervention: Modulating adhesion molecules like ICAM1 or CD58, which show differential patterns, could alter immune cell trafficking and function, influencing therapeutic outcomes.

15. Intestinal Epithelial Cell의 조건 특이적 표면 마커 발현 패턴 분석

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱 데이터를 활용하여 대장(Colon) 조직의 Intestinal Epithelial cell에서 정상(normal) 및 종양(tumor) 조건에 따라 차등적으로 발현되는 표면 마커 유전자들을 식별하고 시각화합니다. 특히, surfaceome_only=True 파라미터를 사용하여 세포 표면에 존재하는 단백질만을 대상으로 하였으며, 각 조건에서 최대 50개의 유전자 마커를 선택하여 발현 패턴을 도트 플롯으로 나타냈습니다. 이는 Intestinal Epithelial cell이 종양의 기원 세포(Tumor origin celltype)임을 고려할 때, 종양 발생 및 진행과 관련된 핵심 표면 마커를 식별하는 데 중점을 둡니다.

Visual Summary

제공된 도트 플롯은 Intestinal Epithelial cell에서 정상(normal) 및 종양(tumor) 조건에 따른 유전자 발현 패턴을 시각적으로 보여줍니다.

• 정상 조건 특이적 마커: 플롯의 왼쪽 상단 파란색 상자 안에 있는 유전자들(예: SLC4A4, PCSK5, CDHR5, HEPACAM2, MUC4, CD44)은 주로 정상 조직 샘플(B_cac10-B_cac7)에서 높은 발현 수준(진한 붉은색)과 높은 발현 세포 비율(큰 점)을 보입니다. 이들 유전자는 종양 샘플에서는 발현이 낮거나 거의 나타나지 않습니다.
• 종양 조건 특이적 마커: 플롯의 오른쪽 하단 파란색 상자 안에 있는 유전자들(예: CEACAM5, EPCAM, CD47, ERBB2, SDC1, LY6E, ITGB1, ITGB4)은 주로 종양 조직 샘플(T_cac1-T_cac9, T_cac10-T_cac16)에서 강하게 발현됩니다. 이들은 정상 샘플에서는 발현이 미미합니다.
• 발현 패턴의 명확한 분리: 정상과 종양 조건을 구분하는 유전자 세트가 매우 뚜렷하게 나타나, 두 조건 간 Intestinal Epithelial cell의 유전자 발현 프로파일에 현저한 차이가 있음을 알 수 있습니다.
• 샘플 내 변동성: 일부 유전자에서는 특정 샘플에서 발현이 상대적으로 높거나 낮은 등 조건 내 샘플 간 약간의 변동성도 관찰되지만, 전반적인 조건 특이적 패턴은 일관됩니다.

Biological Interpretation

이 분석 결과는 대장암 발생 시 Intestinal Epithelial cell의 표면 단백질 구성에 상당한 변화가 있음을 명확히 보여줍니다.

정상 Intestinal Epithelial cell의 특징

• CDHR5 (Cadherin Related Family Member 5) 및 HEPACAM2는 세포-세포 부착 및 장벽 무결성과 관련된 중요한 역할을 하는 것으로 알려져 있습니다. 정상 장 상피세포에서 이들의 높은 발현은 건강한 장 상피의 구조적 안정성과 기능을 반영합니다. GeneCards: CDHR5
• MUC4는 뮤신 단백질로, 상피세포 표면을 보호하고 윤활하는 역할을 합니다. 정상 상태에서 높은 발현은 장 점막 보호에 기여함을 시사합니다. GeneCards: MUC4
• CD44는 세포 부착 분자로 다양한 세포 기능에 관여하지만, 정상 조직에서의 높은 발현은 상피세포의 분화 및 특정 기능과 관련될 수 있습니다. GeneCards: CD44

종양 Intestinal Epithelial cell의 특징

• CEACAM5 (Carcinoembryonic Antigen Related Cell Adhesion Molecule 5) 및 CEACAM6는 대표적인 암태아성 항원(oncofetal antigens)으로, 대장암을 포함한 여러 암종에서 과발현되며 종양 성장, 침윤, 전이 및 항-아폽토시스(anti-apoptosis)에 기여하는 것으로 알려져 있습니다. GeneCards: CEACAM5, GeneCards: CEACAM6
• EPCAM (Epithelial Cell Adhesion Molecule)은 상피세포 마커로 흔히 사용되지만, 종양 세포에서 과발현되는 경향이 있어 암 진행 및 전이에 중요한 역할을 합니다. GeneCards: EPCAM
• CD47은 "don't eat me" 신호로 알려져 있으며, 대식세포의 포식 작용을 회피하여 암 세포가 면역 감시를 피하도록 돕습니다. 이는 종양 미세환경 내 면역 회피 메커니즘을 시사합니다. GeneCards: CD47
• ERBB2 (HER2)는 수용체 티로신 키나아제(receptor tyrosine kinase)로, 여러 암종에서 유전자 증폭 및 과발현되어 종양 성장을 촉진하는 중요한 암유전자입니다. GeneCards: ERBB2
• SDC1 (Syndecan 1), LY6E, ITGB1 (Integrin Beta 1) 및 ITGB4 (Integrin Beta 4)와 같은 유전자들은 세포 외 기질(ECM)과의 상호작용, 세포 이동, 침윤, 증식 및 전이와 관련된 다양한 암 진행 과정을 조절하는 데 관여합니다. 특히 인테그린(integrins)은 암세포의 부착 및 이동에 필수적입니다. GeneCards: SDC1, GeneCards: ITGB1, GeneCards: ITGB4

전반적으로, 종양 특이적 표면 마커의 발현 증가는 Intestinal Epithelial cell이 종양 환경에서 증식, 침윤, 전이 및 면역 회피와 같은 악성 특징을 획득하는 분자적 메커니즘을 반영합니다.

Clinical or Translational Implications

이 분석 결과에서 식별된 조건 특이적 표면 마커들은 대장암의 진단, 예후 예측 및 치료에 중요한 임상적 의미를 가질 수 있습니다.

• 바이오마커 개발: CEACAM5/6, EPCAM, CD47, ERBB2 등은 이미 잘 알려진 암 관련 바이오마커이거나 잠재적인 바이오마커입니다. 이들의 Intestinal Epithelial cell 특이적 과발현은 액체 생검(liquid biopsy)을 통한 순환 종양 세포(circulating tumor cells, CTCs) 검출 또는 조직 생검에서의 진단 패널을 개선하는 데 활용될 수 있습니다.
• 치료 표적: 세포 표면에 발현되는 단백질은 약물 개발에 이상적인 표적이 됩니다. CD47과 ERBB2는 이미 항체 치료제(예: HER2 양성 유방암의 트라스투주맙) 또는 임상 시험 중인 치료제의 표적으로 활발히 연구되고 있습니다. EPCAM, SDC1, ITGB1/4 등도 암 치료를 위한 새로운 항체-약물 접합체(antibody-drug conjugates, ADCs)나 CAR-T 세포 치료의 표적으로 고려될 수 있습니다. PubMed search: CD47 cancer therapy, PubMed search: HER2 cancer therapy
• 질병 진행 모니터링: 특정 마커들의 발현 변화는 질병의 진행 정도나 치료 반응을 모니터링하는 데 활용될 수 있습니다.

향후 이러한 마커들에 대한 기능적 검증 및 전임상/임상 연구를 통해 대장암 진단 및 치료 전략 개발에 기여할 수 있을 것입니다.

16. Surfaceome Marker Characterization of Colon Cell Subtypes

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify cell-type-specific surfaceome markers across various cell subsets found in human colon tissue, focusing particularly on Macrophage subtypes. The plot_markers_and_expression_dot tool was utilized, and parameters were set to specifically search for surfaceome markers (surfaceome_only: True). The resulting dot plot visualizes the expression fraction and mean expression levels of these identified markers across different celltype_subset populations. While the initial query requested "condition-specific markers for Macrophage," the generated plot displays markers that distinguish various cell subtypes from each other, which is crucial for detailed cell type characterization.

Visual Summary

The provided dot plot effectively displays the relative expression patterns of selected markers across a comprehensive list of colon cell subtypes (celltype_subset on the y-axis). Each row represents a distinct cell subtype, and each column corresponds to an identified marker gene.

• Dot Size: Indicates the fraction of cells within a given subtype that express a particular marker. Larger dots denote a higher prevalence of expression.
• Dot Color Intensity: Represents the mean expression level of the marker gene in that cell subtype. Darker red colors signify higher mean expression.
• Red Boxes: Highlight clusters of markers that exhibit highly specific expression patterns within particular cell subtypes, indicating strong distinguishing features.
• The plot clearly differentiates various immune cell populations (B cells, T cells, Macrophages, Mast cells, NK cells) and stromal/epithelial cells (Fibroblast, Intestinal Epithelial cell subtypes like Enterocyte, Goblet cell, Tuft cell, Crypt cell, Paneth cell, Enteroendocrine cell).

Biological Interpretation

Macrophage Subtype Characterization

The analysis successfully identified distinct marker profiles for the various Macrophage subtypes (M1, M2A, M2B, M2C, M2D) present in the colon tissue:

• Macrophage (M1): Exhibits high expression of bona fide surface receptors such as CD36 (a scavenger receptor involved in lipid metabolism and inflammation) [GeneCards: CD36], CLEC7A (Dectin-1) (a C-type lectin receptor crucial for antifungal immunity and M1 polarization) [GeneCards: CLEC7A], CLEC10A (another C-type lectin receptor found on myeloid cells) [GeneCards: CLEC10A], and MSR1 (CD204) (macrophage scavenger receptor 1). The presence of intracellular proteins like *SOCS3* and *PTGS2 (COX-2)*, despite the surfaceome_only filter, suggests that while not surface markers, they are highly characteristic of M1 macrophage identity in this dataset.
• Macrophage (M2A): Shows strong expression of KIT (CD117), a receptor tyrosine kinase and a classic mast cell marker, suggesting a potential shared lineage or specific activation state in this M2A subtype. *GATA2* (a transcription factor) is also noted, again indicating the inclusion of non-surfaceome markers.
• Macrophage (M2B): Displays markers such as *MARCKSL1*, *FABP5*, *EHF*, *RELB*, and *ANXA5*. Most of these are primarily intracellular proteins or transcription factors, which highlights the point about the surfaceome_only parameter.
• Macrophage (M2C): Characterized by markers including FCGR3A (CD16), an Fc receptor commonly found on NK cells, neutrophils, and certain macrophage subsets [GeneCards: FCGR3A], and KLRD1/KLRC1 (NKG2A), which are typically NK cell markers but can be expressed by specific myeloid cells. *GPX2* (intracellular enzyme) is also listed.
• Macrophage (M2D): Identified by markers like *LYZ* (Lysozyme, an intracellular enzyme) and *AGR2* (a secreted protein), further illustrating the inclusion of non-surfaceome markers in the output.

Other Prominent Cell Type Markers

The plot also reveals well-known surfaceome markers for other key immune and stromal populations:

• B cells: Subtypes (Breg, Follicular, MZ, Memory) are distinguished by surface markers such as CD22, CD24, and CD86.
• Plasma cells: Strongly express SDC1 (CD138), a classic plasma cell surface marker [GeneCards: SDC1].
• T cells: Various T cell subtypes are identified by their characteristic markers, including CD4 (T helper cells), CD8A/CD8B (cytotoxic T cells), CTLA4 and ITGAE (CD103) (Treg cells), and CD69 (early activation marker).
• Mast cells: Show strong expression of SRGN and TPSAB1/TPSB2 (Tryptase A/B), consistent with their known profiles.
• Epithelial Cells: Specific intestinal epithelial cells also display distinct markers, such as LGR5 for Crypt cells (stem cell marker) [GeneCards: LGR5], KRT20 for Enterocytes, and MUC2 for Goblet cells.

Marker Specificity

The parameter rem_mkrs_common_in_N_groups_or_more: 3 ensured that the plotted markers are relatively specific, distinguishing individual cell subtypes or small groups of related subtypes rather than being broadly expressed across many cell types. This enhances their utility for precise cell characterization.

Clinical or Translational Implications

The identification of cell-type-specific surfaceome markers, even with the inclusion of some non-surfaceome markers, has significant clinical and translational implications, particularly in the context of colon tissue and disease conditions like cancer:

• Precision Immunophenotyping: These markers can be instrumental for precise identification and quantification of specific immune and stromal cell populations in colon biopsies using techniques like flow cytometry or immunohistochemistry. This can provide valuable insights into the cellular composition of the tumor microenvironment (TME) in colorectal cancer (CRC).
• Therapeutic Targets: The bona fide surfaceome markers (e.g., CD36, CLEC7A, FCGR3A on macrophages; CD138 on plasma cells; CD22/CD24 on B cells; CTLA4/CD103 on T cells) represent promising candidates for targeted therapies. For instance, antibodies targeting specific macrophage surface receptors could be developed to modulate their pro- or anti-tumor functions, which is highly relevant in CRC where macrophage polarization significantly impacts disease progression and treatment response [PubMed search: Macrophage polarization colorectal cancer therapy].
• Biomarkers for Disease Progression and Response: The expression patterns of these cell-type-specific markers could serve as biomarkers to track disease progression, predict patient response to immunotherapies, or monitor treatment efficacy in CRC. Changes in the prevalence or activation state of specific macrophage subtypes, for example, could indicate disease severity or therapeutic success.
• Functional Understanding: While some identified markers are intracellular, their strong and specific association with certain cell types points to unique intracellular pathways or functional states that define these populations, offering avenues for further functional research.

Annotation Notes/Limitations

A notable observation is the presence of several intracellular proteins or transcription factors (e.g., *SOCS3, PTGS2, GATA2, LYZ, XBP1*) among the identified "surfaceome markers," despite the surfaceome_only: True parameter being applied. This suggests a potential limitation in the surfaceome annotation list utilized by the tool, or a broad definition of "surfaceome-associated" that includes genes whose expression is highly correlated with surface markers. While these non-surfaceome markers still contribute to the unique transcriptional profiles of their respective cell types, their non-surface localization should be considered if these markers are pursued for experimental validation involving surface staining or antibody-based targeting. Further validation would be required to confirm the surface localization of all genes presented as "surfaceome markers."

17. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers that distinguish fibroblasts in normal colon tissue from those in colorectal tumor tissue using single-cell RNA sequencing data. By focusing on surfaceome genes, the analysis prioritizes markers with potential for cell-surface targeting and clinical utility. The results are presented as a dot plot showing the mean expression and the fraction of cells expressing each marker across different fibroblast clusters under normal and tumor conditions.

Visual Summary

The dot plot effectively illustrates the differential expression of 30 selected surfaceome markers across various fibroblast clusters (represented as "B_cac" for normal and "T_cac" for tumor, likely indicating sample-derived clusters) under two conditions: "normal" and "tumor".

• Normal Condition Markers: A distinct set of markers, including PRNP, PLPP3, GPNMB, and THY1 (CD90), shows higher mean expression (darker red color) and a greater fraction of expressing cells (larger dot size) predominantly in the "normal" fibroblast clusters (e.g., B_cac11, B_cac14, B_cac7). These markers appear less expressed or absent in tumor-associated fibroblasts.
• Tumor Condition Markers: A broad panel of genes exhibits significantly elevated expression and prevalence in the "tumor" fibroblast clusters (e.g., T_cac6, T_cac8, T_cac1, T_cac7, T_cac14, T_cac2, T_cac3). This region of the plot is characterized by numerous large, dark red dots, indicating high expression in a large fraction of cells. Key markers in this group include F2R, MYADM, PTTG1IP, ITGA1, PDGFRB, ANTXR1, CDH11, CD248, MMP14, NECTIN2, TMEM204, ITGAV, TMEM30A, CD55, LTBR, TMEM123, PDLIM5, FAT1, IFNGR2, EDNRA, ICAM1, MCAM, TMX4, ATP1B3, and LRRC32.
• Heterogeneity within Tumor Fibroblasts: While most tumor-associated markers are broadly expressed across tumor fibroblast clusters, there is some variability. For instance, certain markers like PDGFRB, CD248, CDH11, and MMP14 show consistently high expression across many tumor clusters, whereas others like TMEM204 or NECTIN2 might have slightly lower overall expression or be more restricted to specific tumor clusters.

Biological Interpretation

The observed condition-specific surfaceome profiles highlight a fundamental phenotypic reprogramming of fibroblasts in the colorectal tumor microenvironment.

• Normal Fibroblast Phenotype: Genes like THY1 (CD90) are classic markers for fibroblasts and mesenchymal stem cells, often associated with a quiescent or homeostatic state in normal tissues. PRNP (Prion Protein) has roles in cell adhesion and differentiation, while GPNMB (Glycoprotein NMB) is involved in cell migration and anti-inflammatory responses. These markers likely reflect the normal functions of fibroblasts in maintaining tissue structure and homeostasis in the healthy colon.
• Tumor-Associated Fibroblast (CAF) Phenotype: The significant upregulation of numerous surfaceome markers in tumor fibroblasts indicates their activation into a pro-tumorigenic state, commonly referred to as Cancer-Associated Fibroblasts (CAFs). This activated phenotype is characterized by roles in:
• ECM Remodeling and Invasion: Markers such as MMP14 (Matrix Metalloproteinase 14) and integrins like ITGA1 and ITGAV are crucial for degrading the extracellular matrix (ECM), promoting tumor cell invasion, and facilitating metastasis. GeneCards: MMP14, PubMed search: ITGA1 cancer, PubMed search: ITGAV cancer
• Cell Adhesion and Migration: CDH11 (Cadherin-11) plays a role in cell-cell adhesion and is implicated in tumor progression. ANTXR1 (Anthrax Toxin Receptor 1, also known as TEM8) and CD248 (Endosialin/TEM-1) are highly expressed on tumor endothelium and CAFs, contributing to angiogenesis and tumor growth. GeneCards: CDH11, GeneCards: ANTXR1, GeneCards: CD248
• Growth Factor Signaling and Proliferation: PDGFRB (Platelet-Derived Growth Factor Receptor Beta) and EDNRA (Endothelin Receptor Type A) are key receptors involved in CAF proliferation, survival, and activation by various growth factors in the tumor microenvironment. GeneCards: PDGFRB, GeneCards: EDNRA
• Immune Modulation: CD55 (Decay-accelerating factor) can protect cells from complement-mediated lysis, potentially contributing to immune evasion in the TME. ICAM1 (Intercellular Adhesion Molecule 1) is involved in immune cell trafficking and inflammation. GeneCards: CD55, GeneCards: ICAM1

The diverse set of upregulated markers underscores the multifaceted roles of CAFs in promoting tumor progression in the colon, affecting aspects from ECM dynamics and angiogenesis to immune suppression.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers for fibroblasts in colon cancer holds significant clinical and translational potential:

• Diagnostic and Prognostic Biomarkers: The panel of tumor-specific surfaceome markers (e.g., PDGFRB, CD248, CDH11, MMP14, ANTXR1) could serve as highly specific biomarkers for identifying and characterizing CAFs in colorectal cancer. Their surface localization makes them ideal for detection via immunohistochemistry on tissue biopsies, flow cytometry on dissociated cells, or potentially non-invasively through circulating CAF components. Differential expression patterns could aid in distinguishing early-stage tumors, predicting response to therapy, or assessing prognosis.
• Therapeutic Targets: Given that these markers are predominantly expressed on the cell surface of tumor-associated fibroblasts and play active roles in tumor progression, they represent promising therapeutic targets.
• Receptor Blockade: Inhibitors or antibodies against growth factor receptors like PDGFRB or EDNRA could block pro-tumorigenic signaling pathways in CAFs, thereby inhibiting their activation, proliferation, and ultimately their support for tumor growth. PubMed search: PDGFRB cancer therapy
• Targeting Adhesion and ECM Remodeling: Strategies targeting integrins (e.g., ITGA1, ITGAV), cadherins (CDH11), or matrix metalloproteinases (MMP14) could disrupt CAF-ECM interactions, reduce ECM stiffness, and impede tumor cell invasion and metastasis.
• Specific CAF Depletion/Reprogramming: Highly specific antibodies or antibody-drug conjugates (ADCs) against markers like CD248 (Endosialin) could be developed to selectively deplete or reprogram CAFs, reducing their pro-tumorigenic functions with minimal impact on normal healthy fibroblasts. PubMed search: CD248 cancer therapy This precision targeting approach could enhance treatment efficacy and minimize off-target toxicities.
• CAR-T/NK cell therapy: These surface markers could also serve as targets for engineering Chimeric Antigen Receptor (CAR) T or NK cell therapies specifically designed to eliminate CAFs, thereby modifying the tumor microenvironment to be less immunosuppressive and more permissive to anti-tumor immune responses.
• Experimental Validation: Further research is warranted to experimentally validate the functional significance of these markers in colorectal cancer progression using in vitro models (e.g., CAF-tumor cell co-cultures), ex vivo patient-derived organoids, and in vivo animal models. Such studies would confirm their precise roles and assess the therapeutic potential of targeting these molecules.

18. T cell CD4+ Condition-Specific Surfaceome Markers in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers that distinguish T cell CD4+ populations residing in normal colon tissue from those found in colon tumor tissue. The plot_markers_and_expression_dot tool was used to visualize the expression of the top condition-specific surface markers (up to 30 per condition) across different sub-clusters of T cell CD4+ cells. This provides insight into the phenotypic alterations of CD4+ T cells in the tumor microenvironment compared to normal homeostasis.

Visual Summary

The dot plot effectively illustrates distinct surface marker profiles for T cell CD4+ populations associated with normal versus tumor conditions.

• Normal-Associated T cell CD4+ Clusters: The top seven clusters (labeled B_cac14 through B_cac4) exhibit high and prevalent expression (large, dark red dots) of a small set of markers identified as specific to the normal condition. These include CCR7, AREG, and SELPLG.
• Tumor-Associated T cell CD4+ Clusters: The subsequent clusters (labeled T_cac16 through T_cac13) display high and prevalent expression of a much larger array of markers specific to the tumor condition. Prominent tumor-specific markers showing strong expression in multiple tumor-associated clusters include CTLA4, TNFRSF18 (GITR), FAS, CXCR6, CD63, HLA-DPB1, CD58, JAML, SPN, IL2RB, EVI2A, HLA-DRB1, ENTPD1 (CD39), IL12RB1, ITGB1, TMIGD2, ADAM19, SPPL2A, GPR108, and TNFRSF13B.
• Heterogeneity within Tumor-Associated Cells: There is notable heterogeneity among the tumor-associated CD4+ T cell clusters. For example, T_cac16 shows broad and intense expression of many tumor-specific markers, suggesting a highly activated or distinct functional state. Other tumor-associated clusters, such as T_cac14, T_cac5, T_cac12, T_cac10, and T_cac13, show less widespread or lower expression of these markers, indicating diverse subsets within the tumor microenvironment.
• The red vertical boxes on the Y-axis group the clusters based on their predominant marker expression, clearly separating clusters expressing normal-specific markers from those expressing tumor-specific markers. The bar plots on the right indicate the number of cells contributing to each cluster.

Biological Interpretation

The identified surfaceome markers reveal significant biological shifts in CD4+ T cells within the colon tumor microenvironment.

Normal Homeostasis Markers

• CCR7 (C-C Motif Chemokine Receptor 7) and SELPLG (P-Selectin Glycoprotein Ligand 1, CD162) are characteristic of naive and central memory T cells, involved in lymphatic recirculation and homing to secondary lymphoid organs GeneCards: CCR7, GeneCards: SELPLG. Their enrichment in normal-associated CD4+ T cells suggests a quiescent or surveillance phenotype, maintaining immune readiness in healthy colon tissue.
• AREG (Amphiregulin) is an EGF receptor ligand that can promote cell growth and tissue repair, also expressed by certain regulatory T cells or Th2 cells GeneCards: AREG. Its presence in normal CD4+ T cells could reflect homeostatic functions or specific regulatory subsets.
• Tumor-Associated Phenotypes: The extensive set of tumor-specific surface markers points to highly activated, differentiated, and often dysfunctional or regulatory CD4+ T cell states in the tumor.

Immune Checkpoint and Dysregulation

• CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) is a critical inhibitory immune checkpoint receptor, highly upregulated on exhausted or regulatory T cells in cancer, mediating immune suppression PubMed search: CTLA4 cancer immunology.
• FAS (CD95) is a death receptor. Its expression can lead to activation-induced cell death (AICD) in T cells, contributing to T cell deletion in the tumor microenvironment GeneCards: FAS.
• TNFRSF18 (GITR, Glucocorticoid-Induced TNFR-Related Protein) is a co-stimulatory receptor expressed on activated T cells, particularly regulatory T cells (Tregs), and can modulate their suppressive function GeneCards: TNFRSF18.
• ENTPD1 (CD39) is an ectonucleotidase that plays a crucial role in adenosine metabolism by converting ATP/ADP to AMP, often expressed on Tregs and contributing to an immunosuppressive microenvironment GeneCards: ENTPD1.

Activation, Adhesion, and Trafficking

• HLA-DPB1 and HLA-DRB1 are components of MHC Class II molecules. While primarily expressed by antigen-presenting cells, their expression on CD4+ T cells suggests activation, antigen-experienced states, or specialized regulatory subsets that might present antigens PubMed search: HLA-DR CD4 T cell expression.
• IL2RB (CD122) is a subunit of the IL-2 receptor, crucial for T cell proliferation and survival upon activation GeneCards: IL2RB.
• CXCR6 is a chemokine receptor involved in T cell trafficking to inflammatory sites and tumors, often expressed on memory and Th17 cells PubMed search: CXCR6 tumor T cell trafficking.
• CD58 (LFA-3) and ITGB1 (Integrin beta-1, CD29) are adhesion molecules involved in T cell-APC interactions and cell migration GeneCards: CD58, GeneCards: ITGB1.
• CD63, JAML, and SPN (CD43) are also involved in cell adhesion, migration, and activation processes.

Other Notable Markers

• CCL4 (MIP-1β) is a chemokine produced by activated T cells, which can recruit other immune cells to the tumor site, indicating an inflammatory response GeneCards: CCL4.
• TNFRSF13B (TACI) is a receptor for BAFF and APRIL, typically associated with B cells but also found on some T cells, suggesting complex immune signaling within the TME GeneCards: TNFRSF13B.

The overall picture suggests that CD4+ T cells in colon tumors undergo substantial phenotypic remodeling, characterized by markers associated with chronic activation, exhaustion, immune suppression, altered migratory capacity, and potentially regulatory functions. The heterogeneity within tumor-associated clusters indicates diverse functional subsets contributing to the complex immune landscape of colorectal cancer.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers for CD4+ T cells in colon cancer has several important clinical and translational implications:

• Biomarker Discovery: The identified markers can serve as valuable biomarkers for distinguishing tumor-infiltrating CD4+ T cells from those in normal tissue. Specific combinations of markers, particularly those like CTLA4, TNFRSF18, FAS, CXCR6, HLA-DRB1, IL2RB, and ENTPD1, could be used for characterizing the immune status of the tumor microenvironment in colorectal cancer patients.
• Therapeutic Targets: Several markers are promising candidates for therapeutic intervention:
• CTLA4: Already a proven target for immune checkpoint blockade in various cancers (e.g., ipilimumab) PubMed search: CTLA4 blockade cancer therapy. Its upregulation in tumor-associated CD4+ T cells suggests its blockade could enhance anti-tumor immunity in colorectal cancer.
• TNFRSF18 (GITR): Agonists targeting GITR are under investigation in cancer immunotherapy to boost anti-tumor immune responses, potentially by enhancing effector T cell function and/or modulating Treg activity PubMed search: GITR agonist cancer therapy.
• ENTPD1 (CD39): Inhibitors of CD39 are being developed to counter adenosine-mediated immunosuppression in the TME, representing another promising immunotherapeutic strategy.
• CXCR6: Modulating CXCR6 activity could impact the trafficking and localization of specific CD4+ T cell subsets within the tumor, potentially influencing anti-tumor immunity.
• Patient Stratification: The distinct molecular profiles of CD4+ T cell subsets could enable patient stratification, identifying individuals more likely to respond to specific immunotherapies or those with particular immune evasion mechanisms. For example, patients with a high prevalence of CTLA4-expressing CD4+ T cells might benefit from anti-CTLA4 therapy.
• Mechanistic Insights: The markers provide critical insights into the biological processes at play in the tumor microenvironment, such as immune cell exhaustion, activation, adhesion, and migration. This understanding can guide the development of novel therapeutic strategies and improve our comprehension of tumor-immune interactions in colon cancer.

19. Dysregulation of Cell Cycle Pathway Genes in Intestinal Epithelial Cells of Colon Tumors

[Analysis Visualization Results]...

Analysis Overview

This analysis investigated the expression levels of a predefined set of cell cycle pathway genes within Intestinal Epithelial cells, comparing normal colon tissue samples with tumor samples. The specific metric plotted is the "expressing cell fraction (sample)," which represents the proportion of cells within each sample that express a given gene. This allows for the identification of cell cycle genes whose expression patterns are significantly altered in the tumor microenvironment, specifically within the cell type identified as the tumor's origin.

Visual Summary

The box plots display the expressing cell fraction for 24 distinct cell cycle pathway genes, comparing normal (blue boxes) and tumor (orange boxes) conditions in Intestinal Epithelial cells. A consistent and statistically significant pattern emerges across all depicted genes:

• Increased Expression in Tumor: For every gene presented, the median expressing cell fraction is markedly higher in tumor samples compared to normal samples. This indicates that a greater proportion of Intestinal Epithelial cells in tumor tissue are actively expressing these cell cycle-related genes.
• Statistical Significance: All displayed genes show a statistically significant difference in expression between conditions, with p-values ranging from 0.00142 (YWHAH) to 0.0197 (CDKN1B), confirming a robust distinction.
• Heterogeneity in Tumor: The box plots for tumor samples generally exhibit a wider interquartile range (IQR) and a broader spread of individual sample data points (black dots), suggesting greater variability in the expressing cell fraction among different tumor samples compared to the more tightly clustered normal samples. This heterogeneity could reflect diverse tumor biology or stages across individual patients.
• Prominent Examples: Genes such as YWHAH, MYC, ANAPC11, SKP1, CCND1, CDK4, HDAC2, GSK3B, CDK6, RAD21, PRKDC, BUB3, SMC1A, RBX1, HDAC1, TFDP2, SFN, YWHAG, YWHAB, YWHAZ, and CDKN1B all show this significant upregulation in tumor Intestinal Epithelial cells.

Biological Interpretation

The Intestinal Epithelial cell is identified as the tumor origin celltype. The widespread and statistically significant upregulation of numerous cell cycle pathway genes in these cells within tumor samples strongly indicates a fundamental shift towards increased proliferation and uncontrolled cell division, which are hallmarks of cancer.

• Core Cell Cycle Regulators: Genes like CCND1 (Cyclin D1), CDK4, and CDK6 are critical components of the G1/S phase transition, driving cells into DNA replication. Their consistent upregulation is a direct indicator of accelerated cell cycle progression in tumor cells. GeneCards: CCND1
• Oncogenic Drivers: MYC is a well-established oncogene and transcription factor that promotes cell growth, proliferation, and inhibits differentiation. Its elevated expression is a key event in tumorigenesis. GeneCards: MYC
• Ubiquitin Ligase Components: ANAPC11, SKP1, and RBX1 are components of E3 ubiquitin ligases (Anaphase-Promoting Complex/Cyclosome (APC/C) and SCF complex) that regulate cell cycle progression by targeting specific proteins for degradation. Their increased expression suggests heightened activity of protein degradation machinery, which is crucial for timely cell cycle transitions in highly proliferative cells. UniProt: ANAPC11
• Epigenetic Modifiers: HDAC1 and HDAC2 are histone deacetylases that modify chromatin structure, influencing gene expression, including many cell cycle-related genes. Overexpression of HDACs is frequently observed in cancer and contributes to oncogenic transcriptional programs. GeneCards: HDAC1
• DNA Replication and Repair: RAD21 and SMC1A are part of the cohesin complex, essential for sister chromatid cohesion during cell division and also implicated in DNA repair. Their increased expression might reflect the intense replication stress and potential genomic instability inherent in rapidly dividing cancer cells. GeneCards: RAD21
• Mitotic Checkpoint Proteins: BUB3 is a component of the spindle assembly checkpoint, crucial for ensuring accurate chromosome segregation during mitosis. Its upregulation can be associated with increased mitotic activity or a stressed mitotic process in tumor cells. GeneCards: BUB3
• 14-3-3 Proteins: Genes like YWHAH, YWHAZ, and YWHAQ encode 14-3-3 proteins, which are adapter proteins involved in various cellular processes, including cell cycle regulation, signal transduction, and apoptosis. Their roles in cancer are complex and often context-dependent, but they can contribute to cell survival and proliferation. PubMed search: 14-3-3 proteins cancer cell cycle
• CDKN1B (p27): This gene encodes p27, a cyclin-dependent kinase inhibitor (CDKI) generally considered a tumor suppressor by negatively regulating the cell cycle. While its overall expression median is slightly higher in tumor cells, its wide distribution and the concurrent strong upregulation of pro-proliferative genes suggest that if p27 is expressed, its function might be compromised, or it could reflect a subset of cells undergoing stress or attempting to exit the cell cycle, or even play a pro-tumorigenic role in specific contexts, rather than effectively inhibiting proliferation globally.

Overall, the elevated expressing cell fraction of these cell cycle genes in Intestinal Epithelial cells from tumors strongly supports a highly proliferative phenotype, which is a key characteristic of colon cancer.

Clinical or Translational Implications

The findings have several significant clinical and translational implications:

• Biomarker Potential: The consistently upregulated cell cycle genes, such as MYC, CCND1, CDK4, and HDAC1, could serve as potential diagnostic or prognostic biomarkers for colon cancer. Monitoring their expression specifically in Intestinal Epithelial cells could provide insights into disease progression or therapeutic response.
• Therapeutic Targets: Many of the identified genes are established or emerging therapeutic targets in oncology. For instance, CDK4/6 inhibitors are widely used in certain cancers, and HDAC inhibitors are also employed. The observed upregulation of these targets in the Intestinal Epithelial cells suggests that these cells within colon tumors may be particularly sensitive to such targeted therapies.
• Understanding Tumor Biology: This analysis provides direct evidence of cell cycle dysregulation within the tumor-initiating cell type (Intestinal Epithelial cells) in colon cancer. This deeper understanding can guide the development of novel therapeutic strategies that specifically target the proliferative machinery of these cells.
• Heterogeneity and Resistance: The observed heterogeneity in gene expression within tumor samples highlights the potential for varied responses to therapies and suggests that personalized treatment approaches or combination therapies might be necessary to address distinct proliferative subpopulations within tumors.

20. Gene Ontology (GSA) Analysis of Intestinal Epithelial Cells in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results for Intestinal Epithelial cells obtained from single-cell RNA-seq data of human colon tissue. The analysis identifies gene sets (pathways/terms) that are significantly *upregulated* in specific cellular states. Two main comparisons were performed:

1. Diploid Intestinal Epithelial cells versus Aneuploid Intestinal Epithelial cells (Diploid_vs_others): This compares the transcriptional profiles of intestinal epithelial cells classified as diploid against those classified as aneuploid based on ploidy inference. The results show pathways enriched in diploid cells.
2. Tumor Intestinal Epithelial cells versus other (likely Normal) Intestinal Epithelial cells (tumor_vs_others): This compares intestinal epithelial cells derived from tumor samples against those from non-tumor (normal) samples. The results highlight pathways enriched in tumor-derived epithelial cells.

Visual Summary

Intestinal Epithelial Cell: Diploid vs. Others

The bar plot for "Diploid_vs_others" shows GO terms that are significantly upregulated in Diploid Intestinal Epithelial cells compared to Aneuploid cells. The terms are sorted by their -log(p-val) (left panel) and also show -log(q-val) (right panel), indicating statistical significance.

• Top enriched terms include "Mineral absorption," "Fc gamma R-mediated phagocytosis," "FoxO signaling pathway," "ErbB signaling pathway," "Glycosphingolipid biosynthesis," and "Cellular senescence."
• Key functional categories prominently featured involve fundamental epithelial functions (e.g., "Mineral absorption," "Aldosterone-regulated sodium reabsorption"), various crucial signaling pathways (e.g., "FoxO," "ErbB," "Thyroid hormone," "HIF-1," "mTOR," "p53," "PI3K-Akt," "MAPK," "Estrogen signaling"), cellular quality control and stress responses ("Cellular senescence," "Apoptosis," "Mitophagy"), and structural integrity ("Tight junction").
• Interestingly, several "cancer" related terms (e.g., "Glioma," "Transcriptional misregulation in cancer," "Pancreatic cancer," "Colorectal cancer") are also among the top enriched terms, indicating that genes associated with these broad disease categories are active in diploid cells relative to aneuploid cells.

Intestinal Epithelial Cell: Tumor vs. Others

The bar plot for "tumor_vs_others" displays GO terms that are significantly upregulated in Intestinal Epithelial cells from tumor samples compared to non-tumor cells.

• Top enriched terms include "Ribosome," "Parkinson's disease," "Huntington disease," "Amyotrophic lateral sclerosis," "Protein processing in endoplasmic reticulum," and "Oxidative phosphorylation."
• Prominent functional categories suggest intense cellular activity typical of tumor cells, such as protein synthesis and processing ("Ribosome," "Protein processing in endoplasmic reticulum," "Proteasome," "Ribosome biogenesis in eukaryotes," "Protein export"), altered energy metabolism ("Oxidative phosphorylation," "Citrate cycle (TCA cycle)," "Pyruvate metabolism"), and increased proliferation ("Cell cycle").
• Several neurodegenerative disease terms (e.g., "Parkinson's disease," "Huntington disease," "Amyotrophic lateral sclerosis," "Alzheimer disease," "Prion disease," "Pathways of neurodegeneration") appear highly enriched.
• Pathways related to viral and bacterial infections (e.g., "Coronavirus disease," "Ubiquitin mediated proteolysis," "Salmonella infection," "Shigellosis," "Epstein-Barr virus infection," "Human papillomavirus infection") are also notable.
• "Colorectal cancer" is also an enriched term, directly linking the observed gene expression changes to the disease context.

Biological Interpretation

The Gene Ontology analysis of Intestinal Epithelial cells provides insight into the functional shifts associated with ploidy changes and disease state in the colon.

Insights from Diploid vs. Aneuploid Cells

The upregulation of terms like "Mineral absorption," "Aldosterone-regulated sodium reabsorption," and "Tight junction" in Diploid Intestinal Epithelial cells suggests that these cells maintain typical healthy epithelial functions, including ion transport and barrier integrity. The enrichment of key signaling pathways (FoxO, ErbB, p53, PI3K-Akt, MAPK) along with cellular quality control mechanisms such as "Cellular senescence," "Apoptosis," and "Mitophagy" indicates robust regulatory networks and active surveillance mechanisms in diploid cells. This profile is consistent with a healthy or less perturbed cellular state where growth, metabolism, and stress responses are tightly controlled, potentially preventing the accumulation of damaged or aberrant cells. The presence of "Colorectal cancer" and other cancer-related terms in this context could signify that genes involved in normal epithelial homeostasis, whose dysregulation can contribute to cancer, are appropriately regulated and active in diploid cells.

Insights from Tumor vs. Normal Cells

In contrast, Intestinal Epithelial cells from tumor samples exhibit a distinct biological signature. The striking upregulation of "Ribosome," "Protein processing in endoplasmic reticulum," "Proteasome," and "Cell cycle" pathways reflects the high metabolic demand, rapid protein synthesis, and increased proliferative activity characteristic of cancer cells. Alterations in energy metabolism, highlighted by "Oxidative phosphorylation" and "Citrate cycle (TCA cycle)," are consistent with the metabolic reprogramming observed in many cancers, often involving increased aerobic glycolysis and oxidative phosphorylation to support rapid growth [1].

The unexpected enrichment of numerous neurodegenerative disease pathways (e.g., Parkinson's, Huntington's, Alzheimer's) in tumor cells warrants careful consideration. While these diseases primarily affect the nervous system, they are often characterized by protein misfolding, aggregation, and cellular stress responses involving the ubiquitin-proteasome system, ER stress, and mitochondrial dysfunction [2]. Given the intense protein synthesis and turnover in rapidly proliferating cancer cells, these terms likely reflect a generalized cellular stress response, altered protein homeostasis, or activation of shared molecular pathways involved in managing proteotoxicity, rather than implying neurodegeneration in the colon.

Furthermore, the enrichment of viral and bacterial infection pathways suggests active host-pathogen interactions or inflammatory responses within the tumor microenvironment. Colon cancer progression is often linked to chronic inflammation and dysbiosis of the gut microbiome, which can influence epithelial cell behavior and contribute to carcinogenesis [3]. The direct upregulation of the "Colorectal cancer" pathway in tumor cells confirms the activation of specific disease-associated gene networks.

Clinical or Translational Implications

This analysis highlights key functional distinctions between healthy-like (Diploid) and disease-associated (Aneuploid/Tumor) Intestinal Epithelial cells in the colon.

• Diploid cells appear to maintain crucial homeostatic functions, including barrier integrity and robust cellular quality control. Understanding these protective mechanisms could offer insights into preventing malignant transformation.
• Tumor cells exhibit a strong signature of uncontrolled proliferation, metabolic reprogramming, and heightened cellular stress. Pathways such as ribosome biogenesis, protein processing, cell cycle, and oxidative phosphorylation represent potential targets for therapeutic intervention in colorectal cancer, aiming to disrupt the tumor cells' rapid growth and survival advantages [4].
• The connection between tumor cells and pathways of protein homeostasis (as indicated by neurodegenerative disease terms) suggests that targeting protein quality control systems or stress responses might be a novel therapeutic strategy, potentially exacerbating proteotoxic stress in cancer cells.
• The involvement of infection-related pathways in tumor cells underscores the importance of the tumor microenvironment and host-microbiome interactions in colorectal cancer. This could inform strategies involving modulation of the gut microbiome or targeting inflammation to influence tumor progression.

References

1. Metabolic Reprogramming in Cancer:

• PubMed Search: cancer metabolism "Warburg effect" "oxidative phosphorylation" https://pubmed.ncbi.nlm.nih.gov/?term=cancer+metabolism+%22Warburg+effect%22+%22oxidative+phosphorylation%22

2. Protein Misfolding and Stress Responses (shared mechanisms):

• PubMed Search: protein misfolding "ER stress" "ubiquitin proteasome system" cancer neurodegeneration https://pubmed.ncbi.nlm.nih.gov/?term=protein+misfolding+%22ER+stress%22+%22ubiquitin+proteasome+system%22+cancer+neurodegeneration

3. Gut Microbiome and Colorectal Cancer:

• PubMed Search: gut microbiome colorectal cancer inflammation https://pubmed.ncbi.nlm.nih.gov/?term=gut+microbiome+colorectal+cancer+inflammation

4. Targeting Cancer Metabolism:

• PubMed Search: cancer therapy "metabolic pathways" "ribosome" "cell cycle" https://pubmed.ncbi.nlm.nih.gov/?term=cancer+therapy+%22metabolic+pathways%22+%22ribosome%22+%22cell+cycle%22

21. Gene Set Enrichment Analysis (GSEA) of Intestinal Epithelial Cells, CD4+ T Cells, and Fibroblasts in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results for key cell types in human colon tissue: Intestinal Epithelial Cells, CD4+ T cells, and Fibroblasts. The dot plot visualizes the enrichment of 120 selected pathways across different comparison groups. Each dot's color indicates the Normalized Enrichment Score (NES), where red signifies positive enrichment (upregulation of pathway genes) and blue signifies negative enrichment (downregulation). The size of each dot reflects the statistical significance, specifically -log(p-val), with larger dots indicating higher significance.

The comparisons performed are:

Intestinal Epithelial Cell:

• Diploid_vs_others: Diploid Intestinal Epithelial Cells compared to Aneuploid Intestinal Epithelial Cells.
• tumor_vs_others: Intestinal Epithelial Cells from tumor samples compared to those from normal samples.

T cell CD4+:

• normal_vs_others: CD4+ T cells from normal samples compared to those from tumor samples.
• tumor_vs_others: CD4+ T cells from tumor samples compared to those from normal samples.

Fibroblast:

• normal_vs_others: Fibroblasts from normal samples compared to those from tumor samples.
• tumor_vs_others: Fibroblasts from tumor samples compared to those from normal samples.

(Note: Although "Macrophage" was requested in the query, results for this cell type are not displayed in the provided plot based on the specified parameters.)

Visual Summary

The dot plot effectively highlights pathway enrichments and depletions across different cell types and conditions. A clear distinction is observed between normal/diploid states and tumor states, with tumor conditions generally showing stronger and broader pathway enrichments (larger, darker red dots) for proliferative, metabolic, and oncogenic signaling pathways. Conversely, pathways related to specific immune functions show differential enrichment between normal and tumor-infiltrating T cells. The use of the RdBu_r colormap clearly differentiates positively (red) and negatively (blue) enriched pathways, and varying dot sizes provide immediate insight into statistical significance.

Biological Interpretation

Intestinal Epithelial Cells (Tumor Origin)

As the tumor origin cell type, Intestinal Epithelial Cells (IECs) show profound changes in the tumor microenvironment:

• Diploid IECs (vs. Aneuploid IECs): Diploid IECs show enrichment in core cellular processes such as "Ribosome", "Protein export", "DNA replication", and various metabolic pathways ("Purine metabolism", "Pyrimidine metabolism", "Biosynthesis of unsaturated fatty acids", "Pyruvate metabolism"). This suggests that the diploid epithelial cell population, potentially representing less transformed or normally cycling cells, maintains a baseline of active biosynthesis and proliferation. Depletion of "Apoptosis" indicates survival mechanisms.
• Tumor IECs (vs. Normal IECs): Tumor IECs exhibit a striking enrichment of numerous cancer-associated pathways. This includes "Pathways in cancer" and "Colorectal cancer", along with key oncogenic signaling pathways like "Wnt signaling pathway", "HIF-1 signaling pathway", "PI3K-Akt signaling pathway", "MAPK signaling pathway", "Ras signaling pathway", "p53 signaling pathway", and "mTOR signaling pathway". These pathways drive uncontrolled proliferation, survival, and metabolic reprogramming. Furthermore, significant enrichment in "Ribosome", "Protein export", "DNA replication", "Base excision repair", and multiple metabolic pathways (e.g., "Glycolysis / Gluconeogenesis", "Glutathione metabolism", "Pentose phosphate pathway") underscores the high biosynthetic demand and Warburg effect characteristic of rapidly dividing cancer cells PubMed Search: Cancer metabolism Warburg effect. Depletion of "Adherens junction" further supports a loss of epithelial integrity and increased invasiveness.

CD4+ T Cells

CD4+ T cells, critical components of the adaptive immune response, display altered functional states in the tumor:

• Normal CD4+ T cells (vs. Tumor CD4+ T cells): In the normal context, CD4+ T cells show robust enrichment in classical immune functions such as "Antigen processing and presentation", "Cytokine-cytokine receptor interaction", "IL-17 signaling pathway", "Chemokine signaling pathway", "Leukocyte transendothelial migration", and "T cell receptor signaling pathway". This indicates active immune surveillance and effector functions.
• Tumor CD4+ T cells (vs. Normal CD4+ T cells): CD4+ T cells infiltrating tumors demonstrate a shift away from canonical immune activation. "T cell receptor signaling pathway", "Th17 cell differentiation", and "Antigen processing and presentation" are notably depleted, suggesting T cell anergy or exhaustion within the tumor microenvironment PubMed Search: T cell exhaustion tumor microenvironment. Conversely, there is enrichment of "HIF-1 signaling pathway" and metabolic pathways like "Glycolysis / Gluconeogenesis" and "Pentose phosphate pathway", indicative of metabolic adaptation to the hypoxic and nutrient-deprived tumor environment. A slight enrichment in "Apoptosis" could suggest increased T cell death or susceptibility to elimination.

Fibroblasts

Fibroblasts in the colon show dramatic transformation in the tumor context:

• Normal Fibroblasts (vs. Tumor Fibroblasts): Normal fibroblasts are enriched in pathways related to extracellular matrix (ECM) maintenance and homeostatic signaling, such as "ECM-receptor interaction", "Focal adhesion", and "TGF-beta signaling pathway". These pathways are vital for tissue structure and normal stromal function.
• Tumor Fibroblasts (vs. Normal Fibroblasts): Fibroblasts in tumor samples are highly activated, transforming into Cancer-Associated Fibroblasts (CAFs). They exhibit strong enrichment in "ECM-receptor interaction", "Focal adhesion", "TGF-beta signaling pathway", "HIF-1 signaling pathway", "Wnt signaling pathway", "PI3K-Akt signaling pathway", "MAPK signaling pathway", "Ras signaling pathway", and "Proteoglycans in cancer". These pathways highlight their role in extensive ECM remodeling, promoting angiogenesis, and secreting growth factors and cytokines that foster tumor growth and progression GeneCards: TGFB1. Enrichment in "Cell cycle" and "DNA replication" also points to increased proliferation of these stromal cells.

Cross-Cell Type Observations

• Shared Oncogenic Signaling: "Wnt signaling pathway", "PI3K-Akt signaling pathway", "MAPK signaling pathway", and "Ras signaling pathway" are highly enriched in both tumor IECs and tumor Fibroblasts, highlighting their collaborative roles in tumor progression in the colon microenvironment.
• Hypoxia Response: "HIF-1 signaling pathway" is significantly enriched across tumor IECs, tumor CD4+ T cells, and tumor Fibroblasts. This indicates a pervasive hypoxic environment within the colon tumor, driving adaptive responses in all major cellular components of the tumor ecosystem UniProt: HIF1A.
• Viral/Bacterial Pathways: Several infection-related pathways (e.g., "Human cytomegalovirus infection", "Epstein-Barr virus infection", "Hepatitis B", "Hepatitis C") show differential enrichment in tumor IECs. While not universally enriched, their presence suggests potential interactions between pathogens and tumor development or local inflammatory responses.

Clinical or Translational Implications

The GSEA results provide crucial insights into the biology of colon cancer and its microenvironment, with several potential clinical and translational implications:

• Therapeutic Targets in Tumor IECs: The robust enrichment of well-established oncogenic pathways (Wnt, PI3K-Akt, MAPK, Ras, p53, mTOR) in tumor IECs strongly supports these as primary therapeutic targets for anti-cancer drugs in colorectal cancer. Targeting metabolic reprogramming (e.g., glycolysis, nucleotide synthesis) could also starve cancer cells.
• Immunotherapy Strategies: The observed dysfunction and exhaustion of CD4+ T cells in the tumor microenvironment (depletion of TCR signaling and effector pathways, enrichment of apoptosis) underscore the need for immunotherapeutic approaches that can reinvigorate these cells, such as immune checkpoint inhibitors or adoptive cell therapies PubMed Search: Cancer immunotherapy T cell dysfunction.
• Targeting the Tumor Microenvironment (TME): The significant activation of CAFs, characterized by ECM remodeling and growth factor signaling (TGF-beta, Wnt), suggests that targeting CAFs or their secreted factors could disrupt tumor progression, invasion, and immune suppression. Strategies against components like proteoglycans or focal adhesion pathways in CAFs could improve therapeutic outcomes.
• Hypoxia as a Pan-Cellular Driver: The widespread enrichment of "HIF-1 signaling pathway" across tumor cells, immune cells, and stromal cells highlights hypoxia as a unifying feature of the colon tumor microenvironment. Inhibiting HIF-1 could be a multi-pronged therapeutic strategy to simultaneously impede tumor cell growth, reduce CAF activity, and potentially enhance immune cell function.
• Biomarker Discovery: The identified enriched pathways could serve as potential biomarkers for disease progression, response to therapy, or patient stratification in colorectal cancer. For instance, specific metabolic signatures or CAF activation markers might indicate prognosis or guide treatment decisions.

22. Discussion

The comprehensive single-cell analysis of human colon tissue provides a detailed understanding of the cellular and molecular landscape differentiating normal physiology from colorectal cancer. A central finding is the clear identification of Intestinal Epithelial cells as the tumor origin, with a substantial proportion exhibiting aneuploidy in tumor samples, a hallmark of genomic instability and malignancy. These malignant epithelial cells demonstrate a widespread upregulation of cell cycle genes such as MYC, CCND1, CDK4, and CDK6, reflecting uncontrolled proliferation. Gene Ontology and GSEA further confirm intense metabolic reprogramming, protein synthesis, and activation of oncogenic pathways including Wnt, HIF-1, PI3K-Akt, MAPK, Ras, p53, and mTOR signaling, which collectively drive tumor growth and survival.

The tumor microenvironment undergoes extensive remodeling. While normal colon tissue maintains a balanced cellular composition with robust immune surveillance, the tumor context is characterized by a proportional reduction of overall immune populations and significant shifts within immune cell subsets. Specifically, CD4+ T cells in tumors show an increase in immunosuppressive (Treg), pro-inflammatory (Th22, Th17) populations, and a decrease in T follicular helper cells (Tfh). Their GSEA profile indicates T cell anergy or exhaustion, with depletion of TCR signaling and antigen processing pathways, alongside enrichment in metabolic adaptations like glycolysis and HIF-1 signaling. Similarly, macrophage populations shift from M2A dominance in normal tissue to an M1-dominant state in tumors, accompanied by increased pro-tumorigenic M2B and M2D subsets, suggesting a complex and often contradictory immune response within the TME.

Cell-cell interaction analysis reveals a dramatic loss of productive epithelial-immune crosstalk in tumor tissue, where the top interactions are strikingly confined to T cell-T cell communication or dominated by stromal interactions. Notably, the critical IFN-gamma Type II Receptor (IFNGR) signaling, active in normal immune cells, is significantly diminished in tumor contexts, pointing to a key mechanism of immune evasion. Furthermore, the presence of VSIR (VISTA)-HLA-E interactions on tumor-infiltrating T cells underscores chronic T cell suppression. Conversely, tumor-associated fibroblasts (CAFs) exhibit extensive activation, marked by strong collagen-integrin interactions indicative of desmoplasia. Their gene expression profile highlights enrichment in ECM remodeling, growth factor signaling (TGF-beta, Wnt), and proliferative pathways (Cell cycle, DNA replication), affirming their crucial role in fostering a pro-tumorigenic niche. Surfaceome analysis further identifies key markers such as CEACAM5/6, EPCAM, CD47, and ERBB2 on tumor epithelial cells, and PDGFRB, CD248, and MMP14 on CAFs, providing molecular signatures of these transformed cell states.

Collectively, these findings paint a picture of colorectal cancer as a disease driven by genomic instability and aberrant epithelial cell proliferation, fostered by a profoundly altered and immunosuppressive tumor microenvironment. The coordinated dysregulation across epithelial, immune, and stromal compartments highlights the multifaceted challenges in treating this complex disease.

Hypotheses:

1. The observed aneuploidy in Intestinal Epithelial cells is a primary driver of oncogenic pathway activation (e.g., Wnt, PI3K-Akt) and uncontrolled proliferation in colorectal cancer.
2. The shift towards increased Treg, Th22, and M2B/M2D macrophage populations in the tumor microenvironment is a key mechanism of immune evasion, actively suppressing anti-tumor immune responses and promoting tumor progression.
3. The breakdown of IFN-gamma signaling and the upregulation of immune checkpoints like CTLA4 and VSIR (VISTA) in tumor-infiltrating T cells contribute to T cell exhaustion and limit the efficacy of anti-tumor immunity.
4. Cancer-associated fibroblasts (CAFs) actively remodel the extracellular matrix and secrete pro-tumorigenic factors, creating a supportive niche that facilitates tumor growth, invasion, and immune evasion through pathways like TGF-beta and Wnt signaling.
5. The metabolic reprogramming (e.g., increased glycolysis, altered oxidative phosphorylation) observed across tumor epithelial cells, T cells, and fibroblasts is an adaptive response to the hypoxic tumor microenvironment, supporting rapid proliferation and survival.

Potential therapeutic targets:

1. ERBB2 (HER2): ERBB2 amplification is a well-established oncogenic driver in various cancers and was identified as a recurrent amplification in tumor-associated cells (potentially misclassified Intestinal Epithelial cells) and as an upregulated surface marker on tumor Intestinal Epithelial cells. Evidence: Section 4 highlights frequent ERBB2 amplification (17q12:17q21.31) in tumor-associated cell groups. Section 15 identifies ERBB2 as a highly expressed surface marker on tumor Intestinal Epithelial cells, the tumor origin celltype. Validation: Confirm ERBB2 amplification in Intestinal Epithelial tumor cells via FISH. Evaluate the efficacy of HER2-targeted therapies (e.g., trastuzumab, pertuzumab) in patient-derived organoids or xenograft models with high ERBB2 expression/amplification.
2. CD47: CD47 acts as a 'don't eat me' signal, allowing cancer cells to evade macrophage-mediated phagocytosis. Its upregulation on tumor Intestinal Epithelial cells indicates a key immune evasion mechanism. Evidence: Section 15 identifies CD47 as a highly expressed surface marker on tumor Intestinal Epithelial cells, suggesting it actively contributes to immune evasion in the tumor microenvironment. Validation: Test anti-CD47 antibodies in vitro (e.g., co-culture with macrophages) and in vivo (e.g., syngeneic mouse models or PDX models) to assess enhanced phagocytosis of tumor cells and reduced tumor growth.
3. CTLA4 and VSIR (VISTA): These are immune checkpoint molecules upregulated on tumor-infiltrating T cells, contributing to T cell exhaustion and immunosuppression, a key feature of the colorectal cancer microenvironment. Evidence: Section 18 identifies CTLA4 as a prominent upregulated surface marker on tumor-associated CD4+ T cells. Section 14 highlights VSIR-HLA-E interactions in tumor-infiltrating T cells, suggesting active immune suppression. Validation: Evaluate the efficacy of anti-CTLA4 or anti-VISTA antibodies (alone or in combination) in preclinical models. Monitor T cell activation, proliferation, and cytokine production in response to checkpoint blockade in patient-derived T cells.
4. PDGFRB and Integrin pathways (e.g., ITGA1, ITGAV, ITGB1): PDGFRB is a key receptor for CAF activation and proliferation, while integrins mediate crucial CAF-ECM interactions, driving desmoplasia, tumor growth, and invasion in the tumor microenvironment. Evidence: Section 17 shows PDGFRB, ITGA1, and ITGAV are highly upregulated surface markers on tumor fibroblasts. Section 21's GSEA identifies significant enrichment in 'ECM-receptor interaction', 'Focal adhesion', and 'TGF-beta signaling pathway' in tumor fibroblasts. Section 14 highlights numerous collagen-integrin interactions in tumor fibroblasts. Validation: Investigate PDGFRB inhibitors or integrin-blocking antibodies in in vitro CAF-tumor co-culture models to assess effects on CAF activation, ECM remodeling, and tumor cell invasion. Test these agents in vivo in relevant animal models of colorectal cancer.
5. Cell Cycle Regulators (e.g., CDK4/6, MYC, CCND1): These genes are consistently and significantly upregulated in tumor Intestinal Epithelial cells, indicating uncontrolled proliferation, a hallmark of cancer. Evidence: Section 19 shows a widespread and statistically significant increase in the expressing cell fraction of genes like MYC, CCND1, CDK4, and CDK6 in tumor Intestinal Epithelial cells. Validation: Assess the sensitivity of colorectal cancer cell lines and patient-derived organoids to CDK4/6 inhibitors or drugs targeting MYC pathways. Evaluate the anti-proliferative effects and tumor growth inhibition in xenograft models.

Follow-up validation ideas:

1. Perform spatial transcriptomics or multiplexed immunohistochemistry (e.g., CODEX, IMC) to validate the spatial distribution and co-localization of aneuploid Intestinal Epithelial cells with high cell cycle gene expression, and to map the interaction patterns of immunosuppressive immune cells and activated fibroblasts within the tumor microenvironment.
2. Utilize flow cytometry or mass cytometry (CyTOF) on dissociated tumor and normal samples to quantify the absolute numbers and confirm the phenotypic shifts of T cell subsets (Tregs, Th17, Th22) and macrophage subsets (M1, M2A, M2B, M2D) identified by surface markers (e.g., CTLA4, CD39 for T cells; CD36, FCGR3A for macrophages).
3. Conduct in vitro co-culture experiments using patient-derived tumor organoids or cancer cell lines with immune cells (T cells, macrophages) and fibroblasts to functionally validate the identified cell-cell interaction pathways (e.g., IFN-gamma signaling, VSIR-HLA-E, collagen-integrin) and their impact on immune cell function or tumor growth.
4. Employ CRISPR-Cas9 or shRNA perturbation assays in tumor epithelial cells or CAFs to knockdown/overexpress key oncogenic drivers (e.g., MYC, CCND1, PDGFRB, MMP14) or immune modulators (e.g., CD47, ERBB2) and assess their functional consequences on proliferation, invasion, and immune evasion in vitro and in vivo.
5. Validate recurrent genomic amplifications (e.g., ERBB2) identified in the CNV analysis using FISH (Fluorescence In Situ Hybridization) on tumor tissue sections to confirm amplification status and cellular localization, especially in putative misclassified T cells vs. true epithelial cells.
6. Analyze independent cohorts of colorectal cancer patients using bulk RNA-seq or proteomics to validate the differential expression of key gene sets (e.g., cell cycle genes, metabolic pathways) and surface markers in tumor tissue, correlating findings with clinical outcomes and response to therapy.

Limitations:

This report is based on single-cell RNA sequencing data, which provides a snapshot of cellular states and infers cell-cell interactions. While robust computational methods are used, inferences regarding cell-cell communication, lineage relationships, and functional consequences require experimental validation. The detection of CNVs relies on transcriptional data and may not capture all genomic alterations accurately, as highlighted by the potential cell type misclassification issue in one CNV analysis. Furthermore, the dataset represents a specific cohort and tissue type, and findings may not be universally generalizable to all colorectal cancer subtypes or patient populations. The interpretation of complex GSA/GSEA pathways, especially those with broader biological relevance (e.g., neurodegenerative disease pathways in tumor cells), should be approached with caution, recognizing that they may reflect generalized cellular stress rather than specific disease mechanisms.

23. Query List

1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns. save
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Select Intestinal Epithelial cell cells as tumor-origin, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns.
6. Show and save a population bar plot of minor cell types.
7. Show and save a population bar plot of T cell subsets.
8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
9. Show and save a population bar plot of macrophage subsets.
10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
11. Select Intestinal Epithelial cell cells as tumor-origin, show their ploidy populations as a bar plot, and save the result.
12. Show and save cell-cell interaction patterns involving Intestinal Epithelial cell, Fibroblast, Macrophage, and T cell. Select at most 80 cell-cell interactions per group.
13. Select only genes associated with immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save the result.
14. Find cell-cell interactions involving B cell, Myeloid cell, Stromal cell, T cell, Endothelial cell, and Mast cell that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60.
15. Extract condition-specific markers for Intestinal Epithelial cell, show their expression as a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition.
16. Extract condition-specific markers for Macrophage, show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
17. Extract condition-specific markers for Fibroblast, show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
18. Extract condition-specific markers for T cell CD4+, show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Intestinal Epithelial cell, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
20. Show and save Gene Ontology (GSA) analysis results for Intestinal Epithelial cell as a bar plot.
21. Show Gene Set Enrichment Analysis results for Intestinal Epithelial cell, T cell CD4+, Macrophage, and Fibroblast as a dot plot, and save it. Set the color map to RdBu_r and n_pws_to_show to 120.